



Effect of Mycophenolate Mofetil on Progression of Interstitial Fibrosis and Tubular Atrophy after Kidney Transplantation

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005005
Article Type:	Research
Date Submitted by the Author:	05-Feb-2014
Complete List of Authors:	Mihovilovic, Karlo; University Hospital Merkur, Division of nephrology Maksimovic, Bojana; University Hospital Merkur, Division of nephrology Vojtušek, Ivana; University Hospital Merkur, Division of nephrology Gracin, Sonja; University Hospital Merkur, Division of nephrology Kocman, Branislav; University Hospital Merkur, Department of surgery Gustin, Denis; University hospital Merkur, Department of anesthesiology Vidas, Zeljko; University Hospital Merkur, Department of urology Bulimbasic, Stela; University Hospital Dubrava, Department of pathology Ljubanovic, Danica; University Hospital Dubrava, Department of pathology Matovinovic, Mirjana; University Hospital Merkur, Division of nephrology Knotek, Mladen; University Hospital Merkur, Division of nephrology
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	Pharmacology and therapeutics
Keywords:	Histopathology < PATHOLOGY, TRANSPLANT MEDICINE, Renal transplantation < NEPHROLOGY

SCHOLARONE™
Manuscripts

1
2
3 Effect of Mycophenolate Mofetil on Progression of Interstitial Fibrosis and Tubular
4
5
6 Atrophy after Kidney Transplantation
7
8
9

10 Karlo Mihovilović¹, Bojana Maksimović¹, Ivana Kovačević Vojtušek¹, Sonja Gracin¹,
11
12 Branislav Kocman², Denis Guštin³, Željko Vidas⁴, Stela Bulimbašić⁶, Danica Galešić
13
14 Ljubanović^{5,6}, Mirjana Sabljar Matovinović¹, Mladen Knotek^{1,5}
15
16
17
18
19

20 Clinical Hospital Merkur: ¹Department of Medicine, Renal Division, ²Department of Surgery,
21
22 ³Department of Anaesthesiology, ⁴Department of Urology; ⁵University of Zagreb School of
23
24 Medicine, Zagreb, Croatia, Clinical Hospital Dubrava: ⁶Department of Pathology
25
26
27
28
29

30 **Keywords:** interstitial fibrosis, tubular atrophy, kidney function, myophenolate mofetil
31

32 Word count: Abstract-200
33

34 Manuscript- 2998
35

36 **Number of tables:** 7
37

38 **Number of figures:** 3
39
40

41 **Corresponding author:** Dr. Mladen Knotek
42

43 Department of Medicine, Renal Division
44

45 Clinical Hospital Merkur
46

47 Zajceva 19
48

49 10000 Zagreb
50

51 Croatia
52

53 e-mail: mladen.knotek1@zg.t-com.hr (this e-mail address can be published)
54

55 phone: +38512431123, fax: +38512431123
56
57
58
59
60

1
2
3 Karlo Mihovilović – participated in research design, collecting data, analyzing data and wrote the
4 paper, karlomihovilovic@gmail.com
5

6
7 Bojana Maksimović - participated in collecting and analyzing data, bmaximovic@gmail.com
8

9
10 Ivana Kovačević Vojtušek - participated in collecting data, ikovacevicvojtusek@gmail.com
11

12
13 Sonja Gracin - participated in collecting data, sonja.gracin@gmail.com
14

15
16 Branislav Kocman - participated in collecting data, branislav.kocman@gmail.com
17

18
19 Denis Guštin - participated in collecting data, denis.gustin@zg.t-com.hr
20

21
22 Željko Vidas – participated in collecting data, zeljko.vidas1@zg.t-com.hr
23

24
25 Stela Bulimbašić - participated in collecting and analyzing data, stela.bulimbasic@gmail.com
26

27
28 Danica Galešić Ljubanović – participated in collecting and analyzing data,
29 danica.ljubanovic@zg.htnet.hr
30

31
32 Mirjana Sabljar Matovinović – participated in collecting data, mirjana.sabljar-
33 matovinovic@zg.t-com.hr
34

35
36 Mladen Knotek- proposed research design, analyzed data and participated in writing the paper,
37 mladen.knotek1@zg.t-com.hr
38

39
40 Support and Financial Disclosure Declaration:

41
42 Source of support: Grant by the Ministry of Science, Technology and Sports of the
43 Republic of Croatia to Dr. Mladen Knotek.
44

45
46 Disclosures:

47
48 The authors of this manuscript have no conflicts of interest to disclose.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Abbreviations:
7

8 IF/TA - interstitial fibrosis and tubular atrophy
9

10 MMF - mycophenolate mofetil
11

12 BK - polyoma virus BK
13

14 CNI - calcineurin inhibitors
15

16 DGF - delayed graft function
17

18 eCrCl - estimated creatine clearance
19

20 SPKT - simultaneous pancreas kidney transplantation
21

22 HLA MM – human leukocyte antigen mismatch
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT:

Aims - Chronic transplant dysfunction after kidney transplantation is major reason of kidney graft loss and is caused by immunological and non-immunological factors. There is evidence that mycophenolate mofetil (MMF) may exert a positive effect on renal damage in addition to immunosuppression, by its direct antifibrotic properties. The aim of our study was to retrospectively investigate role of MMF dose on progression of chronic allograft dysfunction and IF/TA.

Methods-This is a retrospective cohort study that included 79 patients with kidney and kidney-pancreas transplantation. Immunosuppression consisted of anti-IL2 antibody induction, MMF, a calcineurin inhibitor \pm steroids. An association of average MMF dose over 1 year post transplant with progression of interstitial fibrosis (Δ ci), tubular atrophy (Δ ct) and estimated creatinine clearance (eCrcl) at 1 year post transplant was evaluated using univariate and multivariate analyses.

Results - Higher average MMF dose was significantly independently associated with better eCrcl at 1 year post transplant ($b=0.21 \pm 0.1$, $p=0.04$). In multiple regression analysis lower Δ ci ($b=-0.2 \pm 0.09$, $p=0.05$) and Δ ct ($b=-0.29 \pm 0.1$, $p=0.02$) were independently associated with greater average MMF dose. There was no correlation between average MMF dose and incidence of acute rejection ($p=0.68$).

Conclusions - Higher average MMF dose over 1 year is associated with better renal function and slower progression of IF/TA, at least partly independent of its immunosuppressive effects.

Strengths and limitations of this study

Important novel finding in our study is that greater average MMF exposure was strongly negatively correlated with IF/TA progression during first year after kidney transplantation. Patients on higher average dose of MMF (up to 4 g daily) during 1 year post transplantation had significantly lower progression of graft interstitial fibrosis and tubular atrophy. This is important finding, because of predictive value of graft IF/TA and should translate into better long-term graft survival. Our study has several shortcomings, such as its retrospective aspect and relatively short study period. As it was not aim of the study, we did not report side effects associated with different dosage of MMF.

INTRODUCTION:

Kidney transplantation significantly improves patient survival and quality of life comparing to dialysis. While significant improvements have been made in the treatment of acute rejection and short survival of transplanted kidney, there has not been major improvement in the long-term survival of transplanted kidney.[1] Chronic transplant dysfunction after kidney transplantation is major cause of kidney graft loss and is evoked by immunological and non-immunological factors.[2, 3] Histology changes that determine chronic transplant dysfunction are interstitial fibrosis and tubular atrophy (IF/TA), arteriosclerosis, arteriolar hyalinosis, glomerulopathy and mesangial matrix expansion.[4] IF/TA is the major pathohistology finding that can be verified on graft biopsies after kidney transplantation and is a predictor of long-term allograft function.[4] Clinical factors that affect progression of IF/TA are: recipient age, HLA mismatch, episodes of severe acute rejection, chronic rejection (esp. antibody-mediated), use of calcineurin inhibitors and BK nephropathy. Avoidance of CNI toxicity is considered as an important step to slow progression of IF/TA.[4-7] Mycophenolate mofetil (MMF) may help lowering CNI toxicity, by allowing lower CNI exposure.[7] MMF reduces the risk of acute allograft rejection, without nephrotoxic side effects and is ideal candidate for long-term calcineurin drug reduction treatment strategies.[7] Retrospective studies of renal recipients who were treated with mycophenolate mofetil comparing azathioprin showed that MMF treated patients had significantly less chronic

1
2
3 allograft dysfunction.[8, 9] Besides being associated with lower acute rejection rates as
4 compared to azathioprin,[10, 11] evidence from animal and human studies suggests that
5
6 MMF may also exert a direct antifibrotic properties due to its antiproliferative action on
7
8 nonimmune cells, including renal tubular cells and vascular smooth muscle cells.[12, 13]
9
10
11
12 The aim of our study was to investigate role of mycophenolate mofetil dose on
13
14 progression of IF/TA in kidney transplant recipients.
15
16
17
18
19

20 PATIENTS AND METHODS:

21 *Patients:*

22
23
24
25
26
27 This is a retrospective study conducted at Clinical Hospital “Mercur”. This study
28
29 represents a part of the posttransplant immune monitoring at the Mercur hospital,
30
31 approved by the Hospital Ethics Committee. The study included 79 patients with kidney
32
33 and kidney-pancreas transplantation, transplanted between 2003 and 2011. Eligible
34
35 patients had to have protocol kidney biopsy at the time of implantation and 12 months
36
37 after transplantation. Exclusion criteria have been: dual kidney transplantation, kidney-
38
39 liver transplantation, use of antithymocyte immunoglobulin, BK nephropathy and
40
41 recurrence of glomerulonephritis after transplantation.
42
43
44
45
46
47

48 *Immunosuppression:*

49
50 Induction immunosuppression consisted of an anti-IL2 antibody (daclizumab or
51
52 basiliximab), calcineurin inhibitor (tacrolimus or cyclosporine), MMF and
53
54 methylprednisolone. Maintenance immunosuppression consisted of a calcineurin
55
56
57
58
59
60

1
2
3 inhibitor (tacrolimus or cyclosporine), MMF ± steroids. Target cyclosporine trough
4 concentrations were 250-350 during first month posttransplant, 200-300 during second to
5
6
7
8 6th month and 100-150 µg/L thereafter. Target tacrolimus trough levels were 10-12
9
10 during first month, 8-10 during second to 6th month and 5-8 µg/L thereafter.

11
12 Mycophenolic acid target trough concentration was aimed to be higher than 7.2 µmol/L
13 with tacrolimus and higher than 5 µmol/L with cyclosporine use.

14
15
16
17 Daclizumab was administered at day 0: 2mg/kg i.v. before opening of vascular
18 anastomosis and at day 14: 2mg/kg i.v.. Basiliximab was administered at day 0: 20 mg
19
20
21
22 i.v. before opening of vascular anastomosis and at day 4: 20 mg i.v..
23

24
25 Steroids have been dosed as follows: day 0: intraoperatively 500 mg of
26
27 methylprednisolone, day 1: 250 mg, day 2: 125mg, day 3: 80 mg and day 4: 40 mg. In
28
29 patients with early steroid withdrawal steroids have been withdrawn at day 5 after
30
31 transplantation. In patients maintained on steroids, nadir dose of prednisone was 5 mg/d,
32
33 achieved by 6 months. The criteria for early elimination of steroids were low
34
35 immunological risk of the recipient (absence of, or low degree of HLA sensitization,
36
37 i.e. PRA <10%) and good immediate renal function, as well as absence of an episode of
38
39 acute rejection within 5 days after the transplantation. Steroids have been reintroduced in
40
41 patients who suffered acute rejection episode.
42
43

44
45 As prophylaxis for viral (HSV, CMV), fungal (Candida spp.) urinary and P. jiroveci
46
47 infections, low-dose fluconazole (for one year), valganciclovir (universally for three
48
49 months) and sulfomethoxazol and trimethoprim (for one year) was used.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 *Renal allograft biopsies:*

9
10 Protocol kidney biopsies were done at implantation, 1, 3, 6 and 12 months after
11 transplantation. For cause biopsies were done in case of unexplained deterioration of
12 renal function, or once weekly in patients with DGF. All rejection episodes were
13 histologically confirmed. Histopathological analysis was performed by either of two
14 pathologists who were blinded for immunosuppression. Acute rejections and chronic
15 allograft scores have been analyzed using Banff 97 classification and its updates.[14, 15]
16
17 All protocol and indication biopsies were analyzed by light microscopy, by
18 immunofluorescence for C4d, and if indicated by immunohistochemistry for BK virus.
19 Biopsies at 1 year post transplant have been also analyzed by electron microscopy for
20 signs of chronic antibody-mediated rejection (transplant glomerulopathy, peritubular
21 capillary basement membrane multilayering).[16]
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 *Clinical outcome parameters:*

40
41 Progression of chronic allograft scores during 1 year posttransplant was calculated by
42 subtracting implantation chronic scores from chronic allograft scores 12 months
43 posttransplant: interstitial fibrosis (Δc_i), tubular atrophy (Δc_t), glomerulosclerosis (Δc_g),
44 mesangial matrix increase (Δm_m), vasculopathy (Δc_v) and arteriolar hyalinosis (Δa_h).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3 greater, patients have been treated with antithymocyte globulin. Antibody-mediated
4
5
6 rejections were treated with steroid pulse and plasmapheresis.

7
8 Average dose of MMF during 1 year posttransplant was calculated from MMF dose at
9
10 month 1, 3, 6 and 12.

11
12
13
14
15 *Statistical analysis:*

16
17 Numerical data are presented as mean \pm SD or median with range in case of not normal
18
19 distribution. Normality of distribution has been tested with Kolmogorov-Smirnov test.
20
21 Correlation between two continuous variables has been tested using Spearman
22
23 nonparametric correlation. Difference between two groups in continuous variables has
24
25 been tested with student t-test or with Mann–Whitney test in non-normally distributed
26
27 variables. The significance of the progression in chronic scores was analyzed using
28
29 Wilcoxon Matched Pairs test. Univariate and multiple linear regression analysis were
30
31 performed to determine predictive factors for progression of chronic allograft scores and
32
33 kidney function at 12 months after transplantation. All variables that were associated with
34
35 respective outcome in bivariate analysis (at $p \leq 0.1$) were included in multivariate
36
37 analysis. Because of colinearity between ci and ct score, only one score was included in
38
39 each multivariate analysis. Statistical significance was considered at $p < 0.05$. All
40
41
42
43
44
45
46 statistical analyses were performed using Statistica 10 (StatSoft, Tulsa, OK, USA).
47
48
49
50
51
52
53
54

55 RESULTS:
56
57
58
59
60

1
2
3
4
5
6 *Patient and transplant characteristics:*
7

8 Patient characteristics are shown in Table 1. Recipients were a mean of 44.67 ± 12.03
9 years old at the time of transplantation, 68 percent of them were male and all were
10 Caucasians. 33 percent of recipients had DGF after transplantation. Donors were a mean
11 of 43.89 ± 15.55 years old and 54 percent of them were male. Number of living donor
12 transplantations was 24 (30 percent). Average daily MMF dose during 1 year
13 posttransplant was 2244 ± 585 mg (1062 – 4000) (Table 5). As expected, there was no
14 correlation of MMF dose with MMF trough concentration ($R=-0.13$; $p=0.28$). Also, there
15 was no correlation between MMF dose with tacrolimus concentration ($R=-0.04$; $p=0.79$).
16
17 Early steroid withdrawal was done in 46 percent of patients after transplantation.
18
19 Incidence of subclinical and clinical acute rejections greater than borderline was 30
20 percent in first year. There was no correlation between average MMF dose and incidence
21 of acute rejection ($p=0.68$).
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 *Factors associating with eCr_{cl}:*
40

41 Kidney function increased during 1st year post transplant. eCr_{cl} at month 3 was $56.98 \pm$
42 15.78 ml/min, at 6 month 58.94 ± 16.94 ml/min and at 12 month 61.47 ± 16.75 ml/min
43 ($p<0.001$; 12 months vs. 3 months) (Figure 1.) eCr_{cl} at 1 year post transplant was greater
44 in SPKT recipients (71.38 ± 13.45 ml/min vs. 57.88 ± 16.47 ml/min; $p=0.001$) and in
45 patients who did not have DGF (64.08 ± 15.87 ml/min vs. 56.15 ± 17.55 ml/min; $p=0.05$).
46
47 Donor age ($R=-0.46$; $p<0.001$) and recipient age ($R=-0.46$; $p<0.001$) negatively
48 correlated with eCr_{cl} at 1 year post transplant, while there was no correlation of renal
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 function with donor and recipient gender, type of donation (deceased *vs.* living), HLA
4 MM, average CNI concentration, steroid-free regimen of immunosuppression, or history
5
6 MM, average CNI concentration, steroid-free regimen of immunosuppression, or history
7
8 of acute rejection (Table 6). In univariate analysis allograft function at 12 month post Tx
9
10 was also negatively correlated with ci (R=-0.34; p=0.002) and ct (R=-0.35; p=0.002) at
11
12 12 month (Figure 2A, Figure 2B). Although MMF dose was positively correlated with
13
14 renal function with borderline significance in univariate analysis, in multivariate analysis
15
16 there was a significant positive association between greater average MMF dose and better
17
18 eCr_{cl} at 12 month post transplant (b=0.21 ± 0.1; p=0.04) (Table 2.).
19
20
21
22
23

24
25 *Factors affecting IF/TA:*
26

27 The average ci score increased from 0.16 ± 0.44 to 0.94 ± 0.86 between implantation and
28
29 month 12 (p<0.001). Average progression of this and other chronic scores during 1 year
30
31 post transplant is shown in suppl. data (Table 7). In univariate analysis Δci (R=-0.37;
32
33 p=0.001) and Δct (R=-0.38; p=0.001) significantly negatively correlated with average
34
35 MMF dose (Figure 3A and 3B, Table 3). There was lower progression of ci score in
36
37 patients on steroid-free immunosuppression (0.47 ± 0.7 *vs.* 1.09 ± 0.87; p=0.002) and in
38
39 those who did not have DGF (0.62 ± 0.74 *vs.* 1.19 ± 0.98; p=0.02). Acute cellular
40
41 rejection, recipient and donor gender, recipient and donor age, HLA MM, deceased *vs.*
42
43 living donor, as well as average concentration of tacrolimus had no significant effect on
44
45 progression of chronic allograft scores. Factors that remained significantly associated
46
47 with progression of ci score in multivariate analysis were ci0 score, donor age, average
48
49 MMF dose, DGF and steroid-free immunosuppression (Table 4.). In multivariate analysis
50
51
52
53
54
55
56
57
58
59
60

1
2
3 only ct0 score, average MMF dose and DGF remained independently associated with 12-
4
5 month progression of ct score (Table 4).
6
7
8
9

10 Discussion:

11
12
13
14
15 The most important novel finding in our study is that greater average MMF exposure was
16
17 strongly negatively correlated with IF/TA progression during first year after kidney
18
19 transplantation. Patients on higher average dose of MMF during 1 year post
20
21 transplantation had significantly lower progression of ci and ct scores. To our knowledge
22
23 this is first study demonstrating that there is a dose-dependent protective effect of MMF
24
25 on graft IF/TA. Lower progression of IF/TA could not be explained with lower
26
27 concentration of CNI, because there was not correlation between tacrolimus
28
29 concentration with IF/TA. Similarly, there was no correlation between average MMF
30
31 dose and tacrolimus ($R=-0.04$; $p=0.79$) or cyclosporine concentration ($R=-0.07$, $p=0.79$).
32
33 In addition, higher average MMF dose was not associated with decreased incidence of
34
35 biopsy proven acute rejection, which suggests that antifibrotic properties of higher MMF
36
37 dose was at least partly independent of its immunosuppressive effects. Higher MMF dose
38
39 had only moderate effect on 1-year renal function, which is consistent with previous
40
41 reports showing that transplanted kidneys undergo pathohistology changes without
42
43 significant early change in kidney function.[17]
44
45
46
47
48
49

50 In the present retrospective study we have confirmed that IF/TA progression occurs in
51
52 first year after kidney transplantation. Several studies have shown that progression of
53
54 IF/TA is correlated with type of immunosuppression.[18] In most transplant centers in
55
56
57
58
59
60

1
2
3 the United States and Europe immunosuppression consists of induction with an anti-IL2R
4 antibody or antithymocyte immunoglobulin and maintenance with a calcineurin inhibitor,
5 MMF and steroids.[19] Studies have reported significant improvement in kidney function
6 in patients on MMF with lower exposition to CNIs, esp. tacrolimus.[20] Recently, in the
7 paper of Kamar *et al.* it has been reported that maintenance kidney transplant patients
8 converted to a higher dose of the mycophenolate sodium (1440 mg daily) with lower
9 tacrolimus concentration had borderline higher eCr_{cl} on month 6 vs. those treated with
10 lower dose of mycophenolate sodium, with usual tacrolimus concentration (eCr_{cl} 49.1 ±
11 11.1 vs. 44.7 ± 11.5 ml/min; p=0.07).[21] Although there was only borderline
12 significance, increased mycophenolate dosing with lower tacrolimus concentration was
13 safe with potential benefit on kidney function.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 Our study also corroborates recently published findings of a *post hoc* joint analysis of the
30 Symphony, FDCC and OptiCept trials, where a lower tacrolimus level and a higher
31 MMF dose were associated with significantly better kidney function at 1 year post
32 transplant.[22] Shortcoming of these studies[17,18] is lack of protocol biopsies. The
33 optimal MMF dosing in patients maintained on contemporary low-dose CNI is still
34 undetermined. However, some results of early MMF registration trials suggest that higher
35 MMF exposure might be beneficial; having in mind that there was no antibody induction
36 in these studies and that CNI was standard dose cyclosporine. Thus, in the Tri-continental
37 study, group treated with 3 g MMF compared with 2 g of MMF showed lower incidence
38 of biopsy proven acute rejection episodes (15.9% vs. 19.7%) within 6 month period
39 selected for the primary efficacy analysis. Similarly, serum creatinine level at 1 year was
40 1.42 ± 0.07 mg/dL in the MMF 3 g group vs. 1.64 ± 0.07 mg/dL in MMF 2 g group.[12]
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In the European mycophenolate mofetil study same trends regarding higher MMF dose
4 were observed.[11] As mentioned before, in these studies there was no antibody
5
6 induction that could have allowed lower dose of cyclosporin with higher dose of MMF
7
8 and there were no protocol biopsies. In a more recent MYSS trial, there was no difference
9
10 in acute rejection rate and renal function between MMF and azathioprine in a
11
12 cyclosporine-based protocol.[19] However in that study only one MMF dose was
13
14 compared to azathioprine[23] and again there were no protocol biopsies.
15
16
17

18
19 Unfortunately adequate prospective MMF dose comparison studies in tacrolimus-based
20
21 protocols with antibody induction are missing. In the Symphony study it was reported
22
23 that patients on tacrolimus-MMF-prednisone maintenance immunosuppression after kidney
24
25 transplantation had better kidney function and graft survival with lower number of acute
26
27 rejection episodes. Patients in that group had highest MMF exposure.[24] Protocols with
28
29 even higher MMF exposure might allow additional CNI sparing, that would decrease side
30
31 effect of CNI (hypertension, diabetes, hyperlipidemia, neurotoxicity).[25]
32
33
34

35
36 Clinical relevance of IF/TA without other concomitant pathology (i.e. recurrent disease
37
38 and chronic antibody-mediated rejection) for prediction of graft deterioration and loss is
39
40 controversial. In El-Zoghby et al. study there was attempt to identify specific causes of
41
42 late kidney allograft failure. The authors found that transplant glomerulopathy was
43
44 responsible for 37 percent loss of functioning grafts, while graft loss due to IF/TA was
45
46 present in 31 percent of cases (with higher frequency in deceased-donor transplants).[26]
47
48
49

50
51 At first glance, these results seem at odd with ours, where there were no signs of chronic
52
53 antibody-mediated rejection. An explanation for this discrepancy in the results of the two
54
55 studies is not completely clear, but the former study included high number of living
56
57
58
59
60

1
2
3 transplants (72.5 percent) with glomerulonephritis as primary disease and with follow-up
4
5 up to 10 years. Transplant glomerulopathy is more frequently seen late posttransplant,
6
7 generally with low incidence. Nevertheless, ours and El-Zoghby study, both
8
9 demonstrated that IF/TA even in absence of other pathology is associated with adverse
10
11 graft outcome. Another important study, the DeKaf study, tried to use various
12
13 histopathologic clusters to differentiate subgroups within diagnosis of IF/TA. They found
14
15 that cluster with more severe fibrosis plus inflammation and arterial lesions had the worst
16
17 prognosis.[27] Although incidence of acute rejection in our study did not vary with MMF
18
19 exposure, increased MMF exposure might suppress mild graft inflammation, below the
20
21 threshold for diagnosing acute rejection. This is subject of our ongoing investigation and
22
23 will be reported separately. An interesting finding of the present study was that early
24
25 steroid withdrawal was not associated with worse IF/TA. At first glance this is at odd
26
27 with the Astellas trial.[23] However, according to our protocol, patients with DGF were
28
29 not included in early steroid withdrawal and Astellas trial, which did not have protocol
30
31 biopsies, reported increased IF/TA in early steroid withdrawal group based on indication
32
33 biopsies performed early posttransplant, thus more likely reflecting donor-derived
34
35 histology changes, rather than effect of steroid withdrawal.[28]

36
37
38 In our study there was only borderline significance of positive association of 1-year eCrCl
39
40 with MMF in univariate analysis. This result is not very surprising since decreased renal
41
42 function is not a very sensitive marker of incipient IF/TA.

43
44
45 Mechanisms by which an average higher exposure to MMF was associated with slower
46
47 progression of IF/TA may be both immune and nonimmune. Because there was no
48
49 difference in incidence of acute rejection with respect to increased MMF exposure in our
50
51
52
53
54
55
56
57
58
59
60

1
2
3 study, we believe that there may be a significant contribution of nonimmune mechanisms
4 in retardation of IF/TA in patients with higher MMF. In line with this, in many
5
6 experimental models it has been shown that MMF has antiproliferative and antifibrotic
7
8 effect.[29-31] In the study of Jiang at al. using rat renal ischemia reperfusion injury, a
9
10 time- and dose-dependent correlation of higher MMF dose with better renal function and
11
12 lower interstitial fibrosis was demonstrated. Suggested potential mechanism was lower
13
14 expression of TGF- β 1 and MCP-1 with lower macrophage infiltration.[32] In recent
15
16 clinical trials MMF was shown as a safe drug that could be a good candidate for
17
18 treatment of interstitial lung disease in systemic sclerosis.[33] Experimental model of
19
20 encapsulated peritoneal sclerosis in rats proved beneficial effect of MMF as an inhibitor
21
22 of neovascularisation.[34] Also, MMF monotherapy was associated with a positive effect
23
24 on hepatic fibrosis progression in HCV liver transplant recipients.[35]

25
26 Our study has several shortcomings, such as its retrospective aspect and relatively short
27
28 study period. Although study period was limited to 12 months post transplantation, a
29
30 clear correlation of slower progression of IF/TA with higher average MMF dose
31
32 underlines potential benefit of these findings. As mentioned before, in current study we
33
34 did not analyze inflammation outside Banff acute rejection threshold in kidney biopsies
35
36 with respect to MMF dose. As inflammation in areas of IF/TA is an important predictor
37
38 of renal function and graft loss, this is subject of an ongoing work.

39
40 In summary, higher MMF dose after kidney transplantation might slower progression of
41
42 IF/TA, which might lead to better long-term survival of transplanted kidney. Our study
43
44 may serve as a platform for a prospective, randomized, long-term trial with different
45
46 MMF doses to evaluate benefit of higher MMF dose in renal transplant recipients.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgments:

This manuscript has not been published elsewhere, beside as a part of 2011 ASN Annual meeting abstract.

Contributorship Statement:

Karlo Mihovilović – participated in research design, collecting data, analyzing data and wrote the paper,

Bojana Maksimović - participated in collecting and analyzing data

Ivana Kovačević Vojtušek - participated in collecting data

Sonja Gracin - participated in collecting data

Branislav Kocman - participated in collecting data

Denis Guštin - participated in collecting data

Željko Vidas – participated in collecting data

Stela Bulimbašić - participated in collecting and analyzing data

Danica Galešić Ljubanović – participated in collecting and analyzing data

Mirjana Sabljar Matovinović – participated in collecting data

Mladen Knotek- proposed research design, analyzed data and participated in writing the paper

Competing Interests

None

Data Sharing Statement

There is no additional data

Reference List

- 1 Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. *N Engl J Med* 2002; 346:580-590.
- 2 Kuypers DR, Chapman JR, O'Connell PJ et al. Predictors of renal transplant histology at three months. *Transplantation* 1999; 67:1222-1230.
- 3 Matas AJ, Gillingham KJ, Payne WD et al. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). *Transplantation* 1994;57:857-859.
- 4 Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. *N Engl J Med* 2003; 349:2326-2333.
- 5 Birnbaum LM, Lipman M, Paraskevas S et al. Management of chronic allograft nephropathy: a systematic review. *Clin J Am Soc Nephrol* 2009; 4:860-865.
- 6 Frimat L, Cassuto-Viguiet E, Charpentier B et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. *Am J Transplant* 2006; 6:2725-2734.
- 7 Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. *N Engl J Med* 2007; 357:2562-2575.
- 8 Azuma H, Binder J, Heemann U et al. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. *Transplantation* 1995; 59:460-466.
- 9 Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. *Transplantation* 2000; 69:2405-2409.
- 10 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. *Transplantation* 1996; 61:722-729.
- 11 European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. *Lancet* 1995; 345, 1321-1325.
- 12 Djamali A, Vidyasagar A, Yagci G et al. Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Nox-2 through the nuclear factor-kappaB pathway. *Transplantation* 2010;90:387-393.
- 13 Dell'Oglio MP, Zaza G, Rossini M et al. The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. *J Am Soc Nephrol* 2010; 21:2157-2168.
- 14 Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. *Am J Transplant* 2008; 8:753-760.
- 15 Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. *Kidney Int* 1999; 55:713-723.
- 16 Roufosse CA, Shore I, Moss J et al. Peritubular capillary basement membrane multilayering on electron microscopy: a useful marker of early chronic antibody-mediated damage. *Transplantation* 2012; 94:269-274.
- 17 Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. *N Engl J Med* 2003; 349:2326-2333.
- 18 Gelens MA, Steegh FM, van Hooff JP et al. Immunosuppressive Regimen and Interstitial Fibrosis and Tubules Atrophy at 12 Months Postrenal Transplant. *Clin J Am Soc Nephrol* 2012; 5:1010-1017.
- 19 Available at:
http://srtr.transplant.hrsa.gov/annual_reports/2011/pdf/01_kidney_12.pdf. 2013.
- 20 Ekberg H, van GT, Kaplan B et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. *Transplantation* 2011; 92:82-87.
- 21 Kamar N, Rostaing L, Cassuto E et al. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. *Clin Nephrol* 2012 ;77:126-136.
- 22 Ekberg H, van GT, Kaplan B et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. *Transplantation* 2011; 92:82-87.
- 23 Remuzzi G, Lesti M, Gotti E et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. *Lancet* 2004; 364:503-512.
- 24 Lloberas N, Torras J, Cruzado JM et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study. *Nephrol Dial Transplant* 2011; 26:3784-3793.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 25 Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. *N Engl J Med* 2002; 346:580-590.
- 26 El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney allograft loss. *Am J Transplant* 2009;9:527-535.
- 27 Matas AJ, Leduc R, Rush D et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. *Am J Transplant* 2010; 10:315-323.
- 28 Woodle ES, First MR, Pirsch J et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. *Ann Surg*; 248: 564-577.
- 29 Luo L, Sun Z, Wu W et al. Mycophenolate mofetil and FK506 have different effects on kidney allograft fibrosis in rats that underwent chronic allograft nephropathy. *BMC Nephrol* 2012;13:53.
- 30 Jiang S, Tang Q, Rong R et al. Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. *Eur J Pharmacol* 2012; 688:56-61.
- 31 Dell'Oglio MP, Zaza G, Rossini M et al. The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. *J Am Soc Nephrol* 2010; 21:2157-2168.
- 32 Jiang S, Tang Q, Rong R et al. Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. *Eur J Pharmacol* 2012; 688:56-61.
- 33 Tzouveleakis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntoliou P, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. *Pulm Med* 2012; 1-7.
- 34 Hur E, Bozkurt D, Timur O, Bicak S, Sarsik B, Akcicek F, et al. The effects of mycophenolate mofetil on encapsulated peritoneal sclerosis model in rats. *Clin Nephrol* 2012; 77:1-7.
- 35 Manzia TM, Angelico R, Toti L et al. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. *Transpl Int* 2011; 24:461-468.

Table 1. Baseline characteristics

RECIPIENT CHARACTERISTICS	AGE (years)	44.67 ± 12.03
	GENDER (f/m)	25/54
	PRIMARY RENAL DISEASE (diabetes mellitus, polycystic kidney disease, glomerulonephritis, pyelonephritis/interstitial nephritis, other/unknown)	24/8/19/6/22
DONOR CHARACTERISTICS	DONOR SOURCE (deceased/living)	55/24
	AGE (years)	43.89 ± 15.55
	GENDER (f/m)	36/43
TRANSPLANTATION CHARACTERISTICS	TRANSPLANTED ORGAN (KIDNEY/SPKT)	58/21
	INITIAL IMMUNOSUPPRESSION (anti-IL2,TAC,MMF/anti-IL2, CyA,MMF)	53/26
	DELAYED GRAFT FUNCTION (no/yes)	53/26
	STEROID FREE (yes/no)	36/43
	HLA MM	3.33 ± 1.51

Table 2. Multiple regression analysis of factors associated with kidney function

	Beta (β)	St.Err. β	p value
Tx (kidney)	-0.17	0.13	0.19
DGF (no)	0.04	0.1	0.71
Recipient age	-0.41	0.1	<0.001
Donor age	-0.1	0.14	0.45
ci at 12 months	-0.18	0.11	0.09
Average MMF dose	0.21	0.1	0.04

Table 3. Correlation of factors associated with progression of ci and ct scores

	Δ ci		Δ ct	
	mean \pm SD	p	mean \pm SD	p
Kidney vs. SPKT	0.86 \pm 0.91 vs. 0.67 \pm 0.73	0.51	0.85 \pm 0.87 vs. 0.86 \pm 0.65	0.74
DGF (yes vs. no)	1.19 \pm 0.98 vs. 0.62 \pm 0.74	0.02	1.15 \pm 0.92 vs. 0.69 \pm 0.72	0.05
Recipient gender (m vs. f)	0.83 \pm 0.88 vs. 0.76 \pm 0.83	0.78	0.91 \pm 0.83 vs. 0.72 \pm 0.79	0.35
Donor gender (m vs. f)	0.91 \pm 0.95 vs. 0.69 \pm 0.75	0.43	0.88 \pm 0.93 vs. 0.81 \pm 0.67	0.96
Donor source (D vs. L)	0.84 \pm 0.88 vs. 0.75 \pm 0.85	0.73	0.87 \pm 0.82 vs. 0.79 \pm 0.83	0.71
Steroid free (yes vs. no)	1.09 \pm 0.87 vs. 0.47 \pm 0.74	0.002	1.07 \pm 0.83 vs. 0.58 \pm 0.73	0.01
Acute rejection (yes vs. no)	0.8 \pm 0.89 vs. 0.83 \pm 0.82	0.78	0.93 \pm 0.84 vs. 0.67 \pm 0.76	0.23
	R	p	R	p
Recipient age	-0.11	0.33	-0.11	0.32
Donor age	0.17	0.13	0.04	0.73
HLA MM	-0.09	0.43	-0.002	0.99
Average tacrolimus conc.	-0.009	0.95	0.003	0.98
Average MMF dose	-0.37	<0.001	-0.38	<0.001
ci at implantation	-0.32	0.003		
ct at implantation			-0.45	<0.001

Table 4. Multivariate general regression analysis for factors related to progression of ci and ct score

Δci			
	Beta (β)	Std. Err. β	p
ci0	-0.43	0.09	<0.001
DGF (no)	-0.22	0.11	<0.05
Average MMF dose	-0.20	0.09	<0.05
Donor age	0.32	0.09	<0.05
Steroid free (yes)	-0.25	0.11	0.02
Δct			
	Beta (β)	Std. Err. β	p
ct0	-0.44	0.09	<0.001
Average MMF dose	-0.29	0.1	<0.05
DGF (no)	-0.29	0.1	<0.05
Steroid free (yes)	-0.09	0.11	0.39

Table 5. eCr_{cl}, MMF dose and CNI concentration during first year post transplant

	Month posttransplant			
	1	3	6	12
eCr _{cl} (ml/min)		56.98 ± 15.79	58.94 ± 16.94	61.47 ± 16.75
MMF dose (mg)	2500 (750 – 4000) 2427 ± 643.17	2000 (750 – 4000) 2167.72 ± 733.49	2000 (1000-4000) 2188.29 ± 716.91	2000 (1000- 4000) 2193.04 ± 642.95
Tacrolimus conc. (µg/L) (n=53)	10.79 ± 4.16	9.69 ± 3.00	9.03 ± 5.52	7.83 ± 2.45
Cyclosporin conc. (µg/L) (n=26)	335.07 (274 – 413)	231.05 (181-265)	206 (170 – 257)	131 (125 – 171)

Table 6. Association of variables with eCr_{cl} on 1 year

	Estimated creatinine clearance (ml/min)	p value
Kidney vs. SPKT	57.88 ± 15.47 vs. 71.38 ± 13.45	0.001
DGF (yes vs. no)	56.15 ± 17.55 vs. 64.08 ± 15.87	0.05
Recipient gender (m vs. f)	59.83 ± 16.02 vs. 65 ± 18.07	0.2
Donor gender (m vs. f)	63.87 ± 16.71 vs. 58.60 ± 16.58	0.17
Donor source (D vs. L)	62.36 ± 17.85 vs. 59.43 ± 14.05	0.47
Steroid-free (yes vs. no)	63.94 ± 17.73 vs. 59.39 ± 15.81	0.23
Acute rejection (yes vs. no)	61.64 ± 16.59 vs. 61.39 ± 16.97	0.95
	R	p value
Recipient age	-0.45	<0.001
Donor age	-0.46	<0.001
HLA MM	0.07	0.52
Average tacrolimus concentration	-0.02	0.9
Average MMF dose	0.18	0.1
ci at 1 year post Tx	-0.34	0.002
ct at 1 year post Tx	-0.35	0.002
cv at 1 year post Tx	-0.20	0.07

Table 7. One-year progression of chronic allograft scores


Banff score	N	At transplantation	N	12 month	p
Interstitial fibrosis (ci)	79	0.16 ± 0.44	79	0.94 ± 0.85	<0.001
Tubular atrophy (ct)	79	0.24 ± 0.46	79	1.05 ± 0.77	<0.001
Chronic glomerulopathy (cg)	79	0	79	0	
Mesangial matrix (mm)	79	0.01 ± 0.11	79	0.09 ± 0.36	0.09
Fibrointimal thickening (cv)	76	0.37 ± 0.83	78	0.29 ± 0.70	0.47
Arteriolar hyalinosis (ah)	78	0.68 ± 1.04	79	0.79 ± 1.04	0.26

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Estimated creatinine clearance during first year posttransplant




*, p<0.001; 3 month vs. 12 months eCrCl. Values are shown as mean ± SD

108x108mm (300 x 300 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 1A: Correlation between average MMF dose and progression of ci score



108x108mm (300 x 300 DPI)




Figure 1B: Correlation between average MMF dose and progression of ct score



108x108mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2A: Estimated creatinine clearance by ci score



* p<0.05; score ci 0 vs. score ci 3 (*post hoc* Newman-Keuls test)


** p=0.03; score ci 1 vs. score ci 3

Values are shown as mean ± SD

108x108mm (300 x 300 DPI)



Figure 2B: Estimated creatinine clearance by ct score



* $p < 0.05$; score ct 0 vs. score ct 3 (post hoc Newman-Keuls test)

** $p = 0.03$; score ct 1 vs. score ct 3

Values are shown as mean \pm SD

108x108mm (300 x 300 DPI)

BMJ

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No/page number	Recommendation
Title and abstract	1/1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2/5	Explain the scientific background and rationale for the investigation being reported
Objectives	3/5,6	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4/6	Present key elements of study design early in the paper
Setting	5/6,7,8,9	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6/6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7/6,7,8	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/measurement	8*/8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10/6	Explain how the study size was arrived at
Quantitative variables	11/9	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12/9	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

Results

Participants	13* /9, 10	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14* /9, 10	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15* /11	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16/ 10, 11	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18/ 12	Summarise key results with reference to study objectives
Limitations	19/ 16	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20/ 12- 16	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21/ 12- 16	Discuss the generalisability (external validity) of the study results

Other information

Funding	22/ 2	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----------	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Effect of Mycophenolate Mofetil on Progression of Interstitial Fibrosis and Tubular Atrophy after Kidney Transplantation- A Retrospective Study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005005.R1
Article Type:	Research
Date Submitted by the Author:	03-May-2014
Complete List of Authors:	Mihovilovic, Karlo; University Hospital Merkur, Division of nephrology Maksimovic, Bojana; University Hospital Merkur, Division of nephrology Kocman, Branislav; University Hospital Merkur, Department of surgery Gustin, Denis; University hospital Merkur, Department of anesthesiology Vidas, Zeljko; University Hospital Merkur, Department of urology Bulimbasic, Stela; University Hospital Dubrava, Department of pathology Ljubanovic, Danica; University Hospital Dubrava, Department of pathology Matovinovic, Mirjana; University Hospital Merkur, Division of nephrology Knotek, Mladen; University Hospital Merkur, Division of nephrology
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	Pharmacology and therapeutics, Renal medicine, Pathology
Keywords:	Histopathology < PATHOLOGY, TRANSPLANT MEDICINE, Renal transplantation < NEPHROLOGY

SCHOLARONE™
Manuscripts

only

1
2
3 **Effect of Mycophenolate Mofetil on Progression of Interstitial Fibrosis and Tubular**
4
5 **Atrophy after Kidney Transplantation - A Retrospective Study**
6
7
8
9

10 Karlo Mihovilović¹, Bojana Maksimović¹, Branislav Kocman², Denis Guštin³, Željko Vidas⁴,
11
12 Stela Bulimbašić⁶, Danica Galešić Ljubanović^{5,6}, Mirjana Sabljar Matovinović¹, Mladen
13
14
15 Knotek^{1,5}
16
17
18
19

20
21 Clinical Hospital Merkur: ¹Department of Medicine, Renal Division, ²Department of Surgery,
22
23 ³Department of Anaesthesiology, ⁴Department of Urology; ⁵University of Zagreb School of
24
25
26 Medicine, Zagreb, Croatia, Clinical Hospital Dubrava: ⁶Department of Pathology
27
28
29

30 **Keywords:** interstitial fibrosis, tubular atrophy, kidney function, myophenolate mofetil
31

32 Word count: Abstract-238
33

34 Manuscript- 3049
35

36 **Number of tables: 8**
37

38 **Number of figures: 3**
39
40

41 **Corresponding author:** Dr. Mladen Knotek
42

43 Department of Medicine, Renal Division
44

45 Clinical Hospital Merkur
46

47 Zajceva 19
48

49 10000 Zagreb
50

51 Croatia
52

53 e-mail: mladen.knotek1@zg.t-com.hr (this e-mail address can be published)
54

55 phone: +38512431123, fax: +38512431123
56
57
58
59
60

ABSTRACT:

Objectives - Chronic transplant dysfunction after kidney transplantation is major reason of kidney graft loss and is caused by immunological and non-immunological factors.

There is evidence that mycophenolate mofetil (MMF) may exert a positive effect on renal damage in addition to immunosuppression, by its direct antifibrotic properties. The aim of our study was to retrospectively investigate role of MMF dose on progression of chronic allograft dysfunction and IF/TA.

Setting - Retrospective, cohort study.

Participants - Kidney transplant patients in tertiary care institution. This is a retrospective cohort study that included 79 patients with kidney and kidney-pancreas transplantation. Immunosuppression consisted of anti-IL2 antibody induction, MMF, a calcineurin inhibitor \pm steroids.

Primary outcome measures - An association of average MMF dose over 1 year post transplant with progression of interstitial fibrosis (Δ ci), tubular atrophy (Δ ct) and estimated creatinine clearance (eCrcl) at 1 year post transplant was evaluated using univariate and multivariate analyses.

Results - Higher average MMF dose was significantly independently associated with better eCrcl at 1 year post transplant ($b=0.21 \pm 0.1$, $p=0.04$). In multiple regression analysis lower Δ ci ($b=-0.2 \pm 0.09$, $p=0.05$) and Δ ct ($b=-0.29 \pm 0.1$, $p=0.02$) were independently associated with greater average MMF dose. There was no correlation between average MMF dose and incidence of acute rejection ($p=0.68$).

1
2
3 **Conclusions** - Higher average MMF dose over 1 year is associated with better renal
4
5 function and slower progression of IF/TA, at least partly independent of its
6
7 immunosuppressive effects.
8
9

10 11 12 **Strengths and limitations of this study**

13
14 Important novel finding in our study is that greater average MMF exposure was strongly
15
16 negatively correlated with IF/TA progression during first year after kidney
17
18 transplantation. Patients on higher average dose of MMF (up to 4 g daily) during 1 year
19
20 post transplantation had significantly lower progression of graft interstitial fibrosis and
21
22 tubular atrophy. This is important finding, because of predictive value of graft IF/TA and
23
24 should translate into better long-term graft survival. Our study has several shortcomings,
25
26 such as its retrospective aspect and relatively short study period. As it was not aim of the
27
28 study, we did not report side effects associated with different dosage of MMF.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION:

Kidney transplantation significantly improves patient survival and quality of life comparing to dialysis. While significant improvements have been made in the treatment of acute rejection and short survival of transplanted kidney, there has not been major improvement in the long-term survival of transplanted kidney.[1] Chronic transplant dysfunction after kidney transplantation is major cause of kidney graft loss and is evoked by immunological and non-immunological factors.[2, 3] Histology changes that determine chronic transplant dysfunction are interstitial fibrosis and tubular atrophy (IF/TA), arteriosclerosis, arteriolar hyalinosis, glomerulopathy and mesangial matrix expansion.[4] IF/TA is the major pathohistology finding that can be verified on graft biopsies after kidney transplantation and is a predictor of long-term allograft function.[4] Clinical factors that affect progression of IF/TA are: recipient age, HLA mismatch, episodes of severe acute rejection, chronic rejection (esp. antibody-mediated), use of calcineurin inhibitors and BK nephropathy. Avoidance of CNI toxicity is considered as an important step to slow progression of IF/TA.[4-7] Mycophenolate mofetil (MMF) may help lowering CNI toxicity, by allowing lower CNI exposure.[7] MMF reduces the risk of acute allograft rejection, without nephrotoxic side effects and is ideal candidate for long-term calcineurin drug reduction treatment strategies.[7] Retrospective studies of renal recipients who were treated with mycophenolate mofetil comparing azathioprin showed that MMF treated patients had significantly less chronic allograft dysfunction.[8, 9] Besides being associated with lower acute rejection rates as compared to azathioprin,[10, 11] evidence from animal and human studies suggests that

1
2
3 MMF may also exert a direct antifibrotic properties due to its antiproliferative action on
4 nonimmune cells, including renal tubular cells and vascular smooth muscle cells.[12, 13]
5
6

7
8 The aim of our study was to investigate role of mycophenolate mofetil dose on
9 progression of IF/TA in kidney transplant recipients.
10
11

12 13 14 15 PATIENTS AND METHODS: 16

17 18 19 20 *Patients:* 21

22 This is a retrospective study conducted at Clinical Hospital “Mercur”. This study
23 represents a part of the posttransplant immune monitoring at the Mercur hospital,
24 approved by the Hospital Ethics Committee. Patients gave there informed written consent for
25 anonymized transplant data collection for research purposes. The study included 79 patients
26 with kidney and kidney-pancreas transplantation, transplanted between 2003 and 2011.
27 Eligible patients had to have protocol kidney biopsy at the time of implantation and 12
28 months after transplantation. Exclusion criteria have been: dual kidney transplantation,
29 kidney-liver transplantation, use of antithymocyte immunoglobulin, BK nephropathy and
30 recurrence of glomerulonephritis after transplantation.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 *Immunosuppression:* 54 55 56 57 58 59 60

1
2
3 Induction immunosuppression consisted of an anti-IL2 antibody (daclizumab or
4 basiliximab), calcineurin inhibitor (tacrolimus or cyclosporine), MMF and
5
6 methylprednisolone. Maintenance immunosuppression consisted of a calcineurin
7
8 inhibitor (tacrolimus or cyclosporine), MMF \pm steroids. Target cyclosporine trough
9
10 concentrations were 250-350 during first month posttransplant, 200-300 during second to
11
12 6th month and 100-150 μ g/L thereafter. Target tacrolimus trough levels were 10-12
13
14 during first month, 8-10 during second to 6th month and 5-8 μ g/L thereafter.
15
16

17
18 Mycophenolic acid target trough concentration was aimed to be higher than 7.2 μ mol/L
19
20 with tacrolimus and higher than 5 μ mol/L with cyclosporine use.
21
22

23
24 Daclizumab was administered at day 0: 2mg/kg i.v. before opening of vascular
25
26 anastomosis and at day 14: 2mg/kg i.v.. Basiliximab was administered at day 0: 20 mg
27
28 i.v. before opening of vascular anastomosis and at day 4: 20 mg i.v..
29
30

31
32 Steroids have been dosed as follows: day 0: intraoperatively 500 mg of
33
34 methylprednisolone, day 1: 250 mg, day 2: 125mg, day 3: 80 mg and day 4: 40 mg. In
35
36 patients with early steroid withdrawal steroids have been withdrawn at day 5 after
37
38 transplantation. In patients maintained on steroids, nadir dose of prednisone was 5 mg/d,
39
40 achieved by 6 months. The criteria for early elimination of steroids were low
41
42 immunological risk of the recipient (absence of, or low degree of HLA sensitization,
43
44 i.e. PRA <10%) and good immediate renal function, as well as absence of an episode of
45
46 acute rejection within 5 days after the transplantation. Steroids have been reintroduced in
47
48 patients who suffered acute rejection episode.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 As prophylaxis for viral (HSV, CMV), fungal (Candida spp.) urinary and P. jiroveci
4
5 infections, low-dose fluconazole (for one year), valganciclovir (universally for three
6
7 months) and sulfomethoxazol and trimethoprim (for one year) was used.
8
9

10
11
12
13
14
15
16
17
18
19
20 *Renal allograft biopsies:*

21
22 Protocol kidney biopsies were done at implantation, 1, 3, 6 and 12 months after
23
24 transplantation. For cause biopsies were done in case of unexplained deterioration of
25
26 renal function, or once weekly in patients with DGF. All rejection episodes were
27
28 histologically confirmed. Histopathological analysis was performed by either of two
29
30 pathologists who were blinded for immunosuppression. Acute rejections and chronic
31
32 allograft scores have been analyzed using Banff 97 classification and its updates.[14, 15]
33
34

35
36 All protocol and indication biopsies were analyzed by light microscopy, by
37
38 immunofluorescence for C4d, and if indicated by immunohistochemistry for BK virus.
39
40 Biopsies at 1 year post transplant have been also analyzed by electron microscopy for
41
42 signs of chronic antibody-mediated rejection (transplant glomerulopathy, peritubular
43
44 capillary basement membrane multilayering).[16]
45
46
47
48

49
50
51 *Clinical outcome parameters:*

52
53 Progression of chronic allograft scores during 1 year posttransplant was calculated by
54
55 subtracting implantation chronic scores from chronic allograft scores 12 months
56
57
58
59
60

1
2
3 posttransplant: interstitial fibrosis (Δci), tubular atrophy (Δct), glomerulosclerosis (Δcg),
4
5 mesangial matrix increase (Δmm), vasculopathy (Δcv) and arteriolar hyalinosis (Δah).
6
7
8 Estimated creatinine clearance (eCr_{cl}) at 3, 6 and 12 months posttransplant was calculated
9
10 using Cockcroft-Gault formula. Acute rejections with Banff grade IA and IB were treated
11
12 with three 500 mg methylprednisolone pulses. In case of acute rejection grade IIA or
13
14 greater, patients have been treated with antithymocyte globulin. Antibody-mediated
15
16 rejections were treated with steroid pulse and plasmapheresis.
17
18

19
20 Average dose of MMF during 1 year posttransplant was calculated from MMF dose at
21
22 month 1, 3, 6 and 12.
23

24
25 Adverse effects analysed were clinically significant leucopenia, defined as white blood
26
27 cell count less than 3000/ml, time to first symptomatic infection and number of
28
29 symptomatic infection episodes per patient during first post transplant year.
30
31

32 33 34 *Statistical analysis:*

35
36 Numerical data are presented as mean \pm SD or median with range in case of not normal
37
38 distribution. Normality of distribution has been tested with Kolmogorov-Smirnov test.
39
40 Correlation between two continuous variables has been tested using Spearman
41
42 nonparametric correlation. Difference between two groups in continuous variables has
43
44 been tested with student t-test or with Mann–Whitney test in non-normally distributed
45
46 variables. The significance of the progression in chronic scores was analyzed using
47
48 Wilcoxon Matched Pairs test. Univariate and multiple linear regression analysis were
49
50 performed to determine predictive factors for progression of chronic allograft scores and
51
52 kidney function at 12 months after transplantation. All variables that were associated with
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

respective outcome in bivariate analysis (at $p \leq 0.1$) were included in multivariate analysis. Because of colinearity between ci and ct score, only one score was included in each multivariate analysis. Statistical significance was considered at $p < 0.05$. All statistical analyses were performed using Statistica 10 (StatSoft, Tulsa, OK, USA).

RESULTS:

Patient and transplant characteristics:

Patient characteristics are shown in Table 1. Recipients were a mean of 44.67 ± 12.03 years old at the time of transplantation, 68 percent of them were male and all were Caucasians. 33 percent of recipients had DGF after transplantation. Donors were a mean of 43.89 ± 15.55 years old and 54 percent of them were male. Number of living donor transplantations was 24 (30 percent). Average daily MMF dose during 1 year posttransplant was 2244 ± 585 mg (1062 – 4000) (Table 2). As expected, there was no correlation of MMF dose with MMF trough concentration ($R = -0.13$; $p = 0.28$). Also, there was no correlation between MMF dose with tacrolimus concentration ($R = -0.04$; $p = 0.79$). Early steroid withdrawal was done in 46 percent of patients after transplantation. Incidence of subclinical and clinical acute rejections greater than borderline was 30 percent in first year. There was no correlation between average MMF dose and incidence of acute rejection ($p = 0.68$).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Factors associating with eCr_{cl}:

Kidney function increased during 1st year post transplant. eCr_{cl} at month 3 was 56.98 ± 15.78 ml/min, at 6 month 58.94 ± 16.94 ml/min and at 12 month 61.47 ± 16.75 ml/min ($p < 0.001$; 12 months vs. 3 months) (Figure 1.) eCr_{cl} at 1 year post transplant was greater in SPKT recipients (71.38 ± 13.45 ml/min vs. 57.88 ± 16.47 ml/min; $p = 0.001$) and in patients who did not have DGF (64.08 ± 15.87 ml/min vs. 56.15 ± 17.55 ml/min; $p = 0.05$). Donor age ($R = -0.46$; $p < 0.001$) and recipient age ($R = -0.46$; $p < 0.001$) negatively correlated with eCr_{cl} at 1 year post transplant, while there was no correlation of renal function with donor and recipient gender, type of donation (deceased vs. living), HLA MM, average CNI concentration, steroid-free regimen of immunosuppression, or history of acute rejection (Table 3). In univariate analysis allograft function at 12 month post Tx was also negatively correlated with ci ($R = -0.34$; $p = 0.002$) and ct ($R = -0.35$; $p = 0.002$) at 12 month (Figure 2A, Figure 2B). Although MMF dose was positively correlated with renal function with borderline significance in univariate analysis, in multivariate analysis there was a significant positive association between greater average MMF dose and better eCr_{cl} at 12 month post transplant ($b = 0.21 \pm 0.1$; $p = 0.04$) (Table 4).

Factors affecting IF/TA:

The average ci score increased from 0.16 ± 0.44 to 0.94 ± 0.86 between implantation and month 12 ($p < 0.001$). Average progression of this and other chronic scores during 1 year post transplant is shown in Table 5. In univariate analysis Δci ($R = -0.37$; $p = 0.001$) and Δct ($R = -0.38$; $p = 0.001$) significantly negatively correlated with average MMF dose (Figure 3A and 3B, Table 6). There was lower progression of ci score in patients on steroid-free

1
2
3 immunosuppression (0.47 ± 0.7 vs. 1.09 ± 0.87 ; $p=0.002$) and in those who did not have
4 DGF (0.62 ± 0.74 vs 1.19 ± 0.98 ; $p=0.02$). Acute cellular rejection, recipient and donor
5 gender, recipient and donor age, HLA MM, deceased vs. living donor, as well as average
6 concentration of tacrolimus had no significant effect on progression of chronic allograft
7 scores. Factors that remained significantly associated with progression of ci score in
8 multivariate analysis were ci0 score, donor age, average MMF dose, DGF and steroid-
9 free immunosuppression (Table 7.). In multivariate analysis only ct0 score, average MMF
10 dose and DGF remained independently associated with 12-month progression of ct score
11 (Table 7.). Selected AE are shown in Table 8. There was no difference in AE (leucopenia
12 and infections) with respect to average median MMF dose.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 Discussion:

30
31
32
33
34 The most important novel finding in our study is that greater average MMF exposure was
35 strongly negatively correlated with IF/TA progression during first year after kidney
36 transplantation. Patients on higher average dose of MMF during 1 year post
37 transplantation had significantly lower progression of ci and ct scores. To our knowledge
38 this is first study demonstrating that there is a dose-dependent protective effect of MMF
39 on graft IF/TA. Lower progression of IF/TA could not be explained with lower
40 concentration of CNI, because there was not correlation between tacrolimus
41 concentration with IF/TA. Similarly, there was no correlation between average MMF
42 dose and tacrolimus ($R=-0.04$; $p=0.79$) or cyclosporine concentration ($R=-0.07$, $p=0.79$).
43
44
45
46
47
48
49
50
51
52
53
54
55
56 In addition, higher average MMF dose was not associated with decreased incidence of
57
58
59
60

1
2
3 biopsy proven acute rejection, which suggests that antifibrotic properties of higher MMF
4 dose was at least partly independent of its immunosuppressive effects. Higher MMF dose
5 had only moderate effect on 1-year renal function, which is consistent with previous
6 reports showing that transplanted kidneys undergo pathohistology changes without
7 significant early change in kidney function.[17]

8
9
10
11
12
13
14
15 In the present retrospective study we have confirmed that IF/TA progression occurs in
16 first year after kidney transplantation. Several studies have shown that progression of
17 IF/TA is correlated with type of immunosuppression.[18] In most transplant centers in
18 the United States and Europe immunosuppression consists of induction with an anti-IL2R
19 antibody or antithymocyte immunoglobulin and maintenance with a calcineurin inhibitor,
20 MMF and steroids.[19] Studies have reported significant improvement in kidney function
21 in patients on MMF with lower exposition to CNIs, esp. tacrolimus.[20] Recently, in the
22 paper of Kamar *et al.* it has been reported that maintenance kidney transplant patients
23 converted to a higher dose of the mycophenolate sodium (1440 mg daily) with lower
24 tacrolimus concentration had borderline higher eCr_{cl} on month 6 vs. those treated with
25 lower dose of mycophenolate sodium, with usual tacrolimus concentration (eCr_{cl} 49.1 ±
26 11.1 vs. 44.7 ± 11.5 ml/min; p=0.07).[21] Although there was only borderline
27 significance, increased mycophenolate dosing with lower tacrolimus concentration was
28 safe with potential benefit on kidney function.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48 Our study also corroborates recently published findings of a *post hoc* joint analysis of the
49 Symphony, FDCC and OptiCept trials, where a lower tacrolimus level and a higher
50 MMF dose were associated with significantly better kidney function at 1 year post
51 transplant.[22] Shortcoming of these studies[17,18] is lack of protocol biopsies. The
52
53
54
55
56
57
58
59
60

1
2
3 optimal MMF dosing in patients maintained on contemporary low-dose CNI is still
4
5 undetermined. However, some results of early MMF registration trials suggest that higher
6
7 MMF exposure might be beneficial; having in mind that there was no antibody induction
8
9 in these studies and that CNI was standard dose cyclosporine. Thus, in the Tri-continental
10
11 study, group treated with 3 g MMF compared with 2 g of MMF showed lower incidence
12
13 of biopsy proven acute rejection episodes (15.9% vs. 19.7%) within 6 month period
14
15 selected for the primary efficacy analysis. Similarly, serum creatinine level at 1 year was
16
17 1.42 ± 0.07 mg/dL in the MMF 3 g group vs. 1.64 ± 0.07 mg/dL in MMF 2 g group.[12]
18
19 In the European mycophenolate mofetil study same trends regarding higher MMF dose
20
21 were observed.[11] As mentioned before, in these studies there was no antibody
22
23 induction that could have allowed lower dose of cyclosporin with higher dose of MMF
24
25 and there were no protocol biopsies. In a more recent MYSS trial, there was no difference
26
27 in acute rejection rate and renal function between MMF and azathioprine in a
28
29 cyclosporine-based protocol.[19] However in that study only one MMF dose was
30
31 compared to azathioprine[23] and again there were no protocol biopsies.
32
33 Unfortunately adequate prospective MMF dose comparison studies in tacrolimus-based
34
35 protocols with antibody induction are missing. In the Symphony study it was reported
36
37 that patients on tacrolimus-MMF-prednisone maintenance immunosuppression after kidney
38
39 transplantation had better kidney function and graft survival with lower number of acute
40
41 rejection episodes. Patients in that group had highest MMF exposure.[24] Protocols with
42
43 even higher MMF exposure might allow additional CNI sparing, that would decrease side
44
45 effect of CNI (hypertension, diabetes, hyperlipidemia, neurotoxicity).[25]
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Clinical relevance of IF/TA without other concomitant pathology (i.e. recurrent disease
4 and chronic antibody-mediated rejection) for prediction of graft deterioration and loss is
5 controversial. In El-Zoghby et al. study there was attempt to identify specific causes of
6
7
8
9
10 late kidney allograft failure. The authors found that transplant glomerulopathy was
11
12 responsible for 37 percent loss of functioning grafts, while graft loss due to IF/TA was
13
14 present in 31 percent of cases (with higher frequency in deceased-donor transplants).[26]
15
16
17 At first glance, these results seem at odd with ours, where there were no signs of chronic
18
19 antibody-mediated rejection. An explanation for this discrepancy in the results of the two
20
21 studies is not completely clear, but the former study included high number of living
22
23 transplants (72.5 percent) with glomerulonephritis as primary disease and with follow-up
24
25 up to 10 years. Transplant glomerulopathy is more frequently seen late posttransplant,
26
27 generally with low incidence. Nevertheless, ours and El-Zoghby study, both
28
29 demonstrated that IF/TA even in absence of other pathology is associated with adverse
30
31 graft outcome. Another important study, the DeKaf study, tried to use various
32
33 histopathologic clusters to differentiate subgroups within diagnosis of IF/TA. They found
34
35 that cluster with more severe fibrosis plus inflammation and arterial lesions had the worst
36
37 prognosis.[27] Although incidence of acute rejection in our study did not vary with MMF
38
39 exposure, increased MMF exposure might suppress mild graft inflammation, below the
40
41 threshold for diagnosing acute rejection. This is subject of our ongoing investigation and
42
43 will be reported separately. An interesting finding of the present study was that early
44
45 steroid withdrawal was not associated with worse IF/TA. At first glance this is at odd
46
47 with the Astellas trial.[23] However, according to our protocol, patients with DGF were
48
49 not included in early steroid withdrawal and Astellas trial, which did not have protocol
50
51
52
53
54
55
56
57
58
59
60

1
2
3 biopsies, reported increased IF/TA in early steroid withdrawal group based on indication
4
5 biopsies performed early posttransplant, thus more likely reflecting donor-derived
6
7 histology changes, rather than effect of steroid withdrawal.[28]
8
9

10
11 In our study there was only borderline significance of positive association of 1-year eCr_{cl}
12
13 with MMF in univariate analysis. This result is not very surprising since decreased renal
14
15 function is not a very sensitive marker of incipient IF/TA.
16

17
18 Mechanisms by which an average higher exposure to MMF was associated with slower
19
20 progression of IF/TA may be both immune and nonimmune. Because there was no
21
22 difference in incidence of acute rejection with respect to increased MMF exposure in our
23
24 study, we believe that there may be a significant contribution of nonimmune mechanisms
25
26 in retardation of IF/TA in patients with higher MMF. In line with this, in many
27
28 experimental models it has been shown that MMF has antiproliferative and antifibrotic
29
30 effect.[29-31] In the study of Jiang at al. using rat renal ischemia reperfusion injury, a
31
32 time- and dose-dependent correlation of higher MMF dose with better renal function and
33
34 lower interstitial fibrosis was demonstrated. Suggested potential mechanism was lower
35
36 expression of TGF- β 1 and MCP-1 with lower macrophage infiltration.[32] In recent
37
38 clinical trials MMF was shown as a safe drug that could be a good candidate for
39
40 treatment of interstitial lung disease in systemic sclerosis.[33] Experimental model of
41
42 encapsulated peritoneal sclerosis in rats proved beneficial effect of MMF as an inhibitor
43
44 of neovascularisation.[34] Also, MMF monotherapy was associated with a positive effect
45
46 on hepatic fibrosis progression in HCV liver transplant recipients.[35]
47
48
49
50

51
52
53 Our study has several shortcomings, such as its retrospective aspect and relatively short
54
55 study period. Although study period was limited to 12 months post transplantation, a
56
57
58
59
60

1
2
3 clear correlation of slower progression of IF/TA with higher average MMF dose
4
5 underlines potential benefit of these findings. As mentioned before, in current study we
6
7 did not analyze inflammation outside Banff acute rejection threshold in kidney biopsies
8
9 with respect to MMF dose. As inflammation in areas of IF/TA is an important predictor
10
11 of renal function and graft loss, this is subject of an ongoing work.
12
13

14
15 In summary, higher MMF dose after kidney transplantation might slower progression of
16
17 IF/TA, which might lead to better long-term survival of transplanted kidney. Our study
18
19 serves as a platform for a prospective, randomized, long-term trial with different MMF
20
21 doses to evaluate benefit of higher MMF dose in renal transplant recipients.
22
23

24
25 (NCT018600183).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgments:

This manuscript has not been published elsewhere, beside as a part of 2011 ASN Annual meeting abstract.

Contributorship Statement

Karlo Mihovilović – participated in research design, collecting data, analyzing data and wrote the paper, karlomihovilovic@gmail.com

Bojana Maksimović - participated in collecting and analyzing data, bmaximovic@gmail.com

Branislav Kocman - participated in collecting data, branislav.kocman@gmail.com

Denis Guštin - participated in collecting data, denis.gustin@zg.t-com.hr

Željko Vidas – participated in collecting data, zeljko.vidas1@zg.t-com.hr

Stela Bulimbašić - participated in collecting and analyzing data, stela.bulimbasic@gmail.com

Danica Galešić Ljubanović – participated in collecting and analyzing data,

danica.ljubanovic@zg.htnet.hr

Mirjana Sabljar Matovinović – participated in collecting data, mirjana.sabljar-

matovinovic@zg.t-com.hr

Mladen Knotek- proposed research design, analyzed data and participated in writing the paper,

mladen.knotek1@zg.t-com.hr

Support and Financial Disclosure Declaration:

Source of support: Grant by the Ministry of Science, Technology and Sports of the Republic of Croatia to Dr. Mladen Knotek.

Disclosures:

The authors of this manuscript have no conflicts of interest to disclose.

Data Sharing Statement: No additional data available.

Abbreviations:

IF/TA - interstitial fibrosis and tubular atrophy

MMF - mycophenolate mofetil

BK - polyoma virus BK

CNI - calcineurin inhibitors

DGF - delayed graft function

eCrCl - estimated creatine clearance

SPKT - simultaneous pancreas kidney transplantation

HLA MM – human leukocyte antigen mismatch

AE - adverse events

Figure Legends

Figure 1: Estimated creatinine clearance during first year posttransplant

Figure 2A: Correlation between average MMF dose and progression of ci score

Figure 2B: Correlation between average MMF dose and progression of ct score

Figure 3A: Estimated creatinine clearance by ci score

Figure 3B: Estimated creatinine clearance by ct score

Reference List

- 1 Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. *N Engl J Med* 2002; 346:580-590.
- 2 Kuypers DR, Chapman JR, O'Connell PJ et al. Predictors of renal transplant histology at three months. *Transplantation* 1999; 67:1222-1230.
- 3 Matas AJ, Gillingham KJ, Payne WD et al. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). *Transplantation* 1994;57:857-859.
- 4 Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. *N Engl J Med* 2003; 349:2326-2333.
- 5 Birnbaum LM, Lipman M, Paraskevas S et al. Management of chronic allograft nephropathy: a systematic review. *Clin J Am Soc Nephrol* 2009; 4:860-865.
- 6 Frimat L, Cassuto-Viguiet E, Charpentier B et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. *Am J Transplant* 2006; 6:2725-2734.
- 7 Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. *N Engl J Med* 2007; 357:2562-2575.
- 8 Azuma H, Binder J, Heemann U et al. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. *Transplantation* 1995; 59:460-466.
- 9 Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. *Transplantation* 2000; 69:2405-2409.
- 10 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. *Transplantation* 1996; 61,722-729.
- 11 European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. *Lancet* 1995; 345, 1321-1325.
- 12 Djamali A, Vidyasagar A, Yagci G et al. Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway. *Transplantation* 2010;90:387-393.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 13 Dell'Oglio MP, Zaza G, Rossini M et al. The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. *J Am Soc Nephrol* 2010; 21:2157-2168.
 - 14 Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. *Am J Transplant* 2008; 8:753-760.
 - 15 Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. *Kidney Int* 1999; 55:713-723.
 - 16 Roufosse CA, Shore I, Moss J et al. Peritubular capillary basement membrane multilayering on electron microscopy: a useful marker of early chronic antibody-mediated damage. *Transplantation* 2012; 94:269-274.
 - 17 Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. *N Engl J Med* 2003; 349:2326-2333.
 - 18 Gelens MA, Steegh FM, van Hooff JP et al. Immunosuppressive Regimen and Interstitial Fibrosis and Tubules Atrophy at 12 Months Postrenal Transplant. *Clin J Am Soc Nephrol* 2012; 5:1010-1017.
 - 19 Available at:
http://srtr.transplant.hrsa.gov/annual_reports/2011/pdf/01_kidney_12.pdf. 2013.
 - 20 Ekberg H, van GT, Kaplan B et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. *Transplantation* 2011; 92:82-87.
 - 21 Kamar N, Rostaing L, Cassuto E et al. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. *Clin Nephrol* 2012 ;77:126-136.
 - 22 Ekberg H, van GT, Kaplan B et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. *Transplantation* 2011; 92:82-87.
 - 23 Remuzzi G, Lesti M, Gotti E et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. *Lancet* 2004; 364:503-512.
 - 24 Lloberas N, Torras J, Cruzado JM et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study. *Nephrol Dial Transplant* 2011; 26:3784-3793.
 - 25 Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. *N Engl J Med* 2002; 346:580-590.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 26 El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney allograft loss. *Am J Transplant* 2009;9:527-535.
- 27 Matas AJ, Leduc R, Rush D et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. *Am J Transplant* 2010; 10:315-323.
- 28 Woodle ES, First MR, Pirsch J et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. *Ann Surg*; 248: 564-577.
- 29 Luo L, Sun Z, Wu W et al. Mycophenolate mofetil and FK506 have different effects on kidney allograft fibrosis in rats that underwent chronic allograft nephropathy. *BMC Nephrol* 2012;13:53.
- 30 Jiang S, Tang Q, Rong R et al. Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. *Eur J Pharmacol* 2012; 688:56-61.
- 31 Dell'Oglio MP, Zaza G, Rossini M et al. The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. *J Am Soc Nephrol* 2010; 21:2157-2168.
- 32 Jiang S, Tang Q, Rong R et al. Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. *Eur J Pharmacol* 2012; 688:56-61.
- 33 Tzouveleakis A, Galanopoulos N, Bouros E, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. *Pulm Med* 2012; 1-7.
- 34 Hur E, Bozkurt D, Timur O, et al. The effects of mycophenolate mofetil on encapsulated peritoneal sclerosis model in rats. *Clin Nephrol* 2012; 77:1-7.
- 35 Manzia TM, Angelico R, Toti L et al. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. *Transpl Int* 2011; 24:461-468.

Table 1. Baseline characteristics

RECIPIENT CHARACTERISTICS	AGE (years)	44.67 ± 12.03
	GENDER (f/m)	25/54
	PRIMARY RENAL DISEASE (diabetes mellitus, polycystic kidney disease, glomerulonephritis, pyelonephritis/interstitial nephritis, other/unknown)	24/8/19/6/22
DONOR CHARACTERISTICS	DONOR SOURCE (deceased/living)	55/24
	AGE (years)	43.89 ± 15.55
	GENDER (f/m)	36/43
TRANSPLANTATION CHARACTERISTICS	TRANSPLANTED ORGAN (KIDNEY/SPKT)	58/21
	INITIAL IMMUNOSUPPRESSION (anti-IL2,TAC,MMF/anti-IL2, CyA,MMF)	53/26
	DELAYED GRAFT FUNCTION (no/yes)	53/26
	STEROID FREE (yes/no)	36/43
	HLA MM	3.33 ± 1.51

Table 2. eCr_{cl}, MMF dose and CNI concentration during first year post transplant

	Month posttransplant			
	1	3	6	12
eCr _{cl} (ml/min)		56.98 ± 15.79	58.94 ± 16.94	61.47 ± 16.75
MMF dose (mg)	2500 (750 – 4000) 2427 ± 643.17	2000 (750 – 4000) 2167.72 ± 733.49	2000 (1000-4000) 2188.29 ± 716.91	2000 (1000-4000) 2193.04 ± 642.95
Tacrolimus conc. (µg/L) (n=53)	10.79 ± 4.16	9.69 ± 3.00	9.03 ± 5.52	7.83 ± 2.45
Cyclosporin conc. (µg/L) (n=26)	335.07 (274 – 413)	231.05 (181-265)	206 (170 – 257)	131 (125 – 171)

Table 3. Association of variables with eCr_{cl} on 1 year

	Estimated creatinine clearance (ml/min)	p value
Kidney vs. SPKT	57.88 ± 15.47 vs. 71.38 ± 13.45	0.001
DGF (yes vs. no)	56.15 ± 17.55 vs. 64.08 ± 15.87	0.05
Recipient gender (m vs. f)	59.83 ± 16.02 vs. 65 ± 18.07	0.2
Donor gender (m vs. f)	63.87 ± 16.71 vs. 58.60 ± 16.58	0.17
Donor source (D vs. L)	62.36 ± 17.85 vs. 59.43 ± 14.05	0.47
Steroid-free (yes vs. no)	63.94 ± 17.73 vs. 59.39 ± 15.81	0.23
Acute rejection (yes vs. no)	61.64 ± 16.59 vs. 61.39 ± 16.97	0.95
	R	p value
Recipient age	-0.45	<0.001
Donor age	-0.46	<0.001
HLA MM	0.07	0.52
Average tacrolimus concentration	-0.02	0.9
Average MMF dose	0.18	0.1
ci at 1 year post Tx	-0.34	0.002
ct at 1 year post Tx	-0.35	0.002
cv at 1 year post Tx	-0.20	0.07

Table 4. Multiple regression analysis of factors associated with kidney function

	Beta (β)	St.Err. β	p value
Tx (kidney)	-0.17	0.13	0.19
DGF (no)	0.04	0.1	0.71
Recipient age	-0.41	0.1	<0.001
Donor age	-0.1	0.14	0.45
ci at 12 months	-0.18	0.11	0.09
Average MMF dose	0.21	0.1	0.04

Table 5. One-year progression of chronic allograft scores

Banff score	N	At transplantation	N	12 month	p
Interstitial fibrosis (ci)	79	0.16 ± 0.44	79	0.94 ± 0.85	<0.001
Tubular atrophy (ct)	79	0.24 ± 0.46	79	1.05 ± 0.77	<0.001
Chronic glomerulopathy (cg)	79	0	79	0	
Mesangial matrix (mm)	79	0.01 ± 0.11	79	0.09 ± 0.36	0.09
Fibrointimal thickening (cv)	76	0.37 ± 0.83	78	0.29 ± 0.70	0.47
Arteriolar hyalinosis (ah)	78	0.68 ± 1.04	79	0.79 ± 1.04	0.26

Table 6. Correlation of factors associated with progression of ci and ct scores

	Δ ci		Δ ct	
	mean \pm SD	p	mean \pm SD	p
Kidney vs. SPKT	0.86 \pm 0.91 vs. 0.67 \pm 0.73	0.51	0.85 \pm 0.87 vs. 0.86 \pm 0.65	0.74
DGF (yes vs. no)	1.19 \pm 0.98 vs. 0.62 \pm 0.74	0.02	1.15 \pm 0.92 vs. 0.69 \pm 0.72	0.05
Recipient gender (m vs. f)	0.83 \pm 0.88 vs. 0.76 \pm 0.83	0.78	0.91 \pm 0.83 vs. 0.72 \pm 0.79	0.35
Donor gender (m vs. f)	0.91 \pm 0.95 vs. 0.69 \pm 0.75	0.43	0.88 \pm 0.93 vs. 0.81 \pm 0.67	0.96
Donor source (D vs. L)	0.84 \pm 0.88 vs. 0.75 \pm 0.85	0.73	0.87 \pm 0.82 vs. 0.79 \pm 0.83	0.71
Steroid free (yes vs. no)	1.09 \pm 0.87 vs. 0.47 \pm 0.74	0.002	1.07 \pm 0.83 vs. 0.58 \pm 0.73	0.01
Acute rejection (yes vs. no)	0.8 \pm 0.89 vs. 0.83 \pm 0.82	0.78	0.93 \pm 0.84 vs. 0.67 \pm 0.76	0.23
	R	p	R	p
Recipient age	-0.11	0.33	-0.11	0.32
Donor age	0.17	0.13	0.04	0.73
HLA MM	-0.09	0.43	-0.002	0.99
Average tacrolimus conc.	-0.009	0.95	0.003	0.98
Average MMF dose	-0.37	<0.001	-0.38	<0.001
ci at implantation	-0.32	0.003		
ct at implantation			-0.45	<0.001

Table 7. Multivariate general regression analysis for factors related to progression of ci and ct score

Δci			
	Beta (β)	Std. Err. β	p
ci0	-0.43	0.09	<0.001
DGF (no)	-0.22	0.11	<0.05
Average MMF dose	-0.20	0.09	<0.05
Donor age	0.32	0.09	<0.05
Steroid free (yes)	-0.25	0.11	0.02
Δct			
	Beta (β)	Std. Err. β	p
ct0	-0.44	0.09	<0.001
Average MMF dose	-0.29	0.1	<0.05
DGF (no)	-0.29	0.1	<0.05
Steroid free (yes)	-0.09	0.11	0.39

Table 8. Adverse events with respect to 1 year average median MMF dose.

	MMF dose < median	MMF dose > median	p
Average number of infection episodes per patient	1.16 ± 0.97	1.23 ± 1.22	0.88
Mean time to first infection (days)	157±138	175±143	0.76
Proportion of patients with leucopenia	6 /31	7 /48	0.58

Effect of Mycophenolate Mofetil on Progression of Interstitial Fibrosis and Tubular
Atrophy after Kidney Transplantation - [A Retrospective Study](#)

Karlo Mihovilović¹, Bojana Maksimović¹, Branislav Kocman², Denis Guštin³, Željko Vidas⁴,
Stela Bulimbašić⁶, Danica Galešić Ljubanović^{5,6}, Mirjana Sabljar Matovinović¹, Mladen
Knotek^{1,5}

Clinical Hospital Merkur: ¹Department of Medicine, Renal Division, ²Department of Surgery,
³Department of Anaesthesiology, ⁴Department of Urology; ⁵University of Zagreb School of
Medicine, Zagreb, Croatia, Clinical Hospital Dubrava: ⁶Department of Pathology

Keywords: interstitial fibrosis, tubular atrophy, kidney function, myophenolate mofetil

Word count: Abstract-238

Manuscript- 3049

Number of tables: 8

Number of figures: 3

Corresponding author: Dr. Mladen Knotek

Department of Medicine, Renal Division

Clinical Hospital Merkur

Zajceva 19

10000 Zagreb

Croatia

e-mail: mladen.knotek1@zg.t-com.hr (this e-mail address can be published)

phone: +38512431123, fax: +38512431123

1
2
3 Karlo Mihovilović – participated in research design, collecting data, analyzing data and wrote the
4 paper, karlomihovilovic@gmail.com
5

6
7 Bojana Maksimović - participated in collecting and analyzing data, bmaximovic@gmail.com
8

9
10 Branislav Kocman - participated in collecting data, branislav.kocman@gmail.com
11

12 Denis Guštin - participated in collecting data, denis.gustin@zg.t-com.hr
13

14 Željko Vidas – participated in collecting data, zeljko.vidas1@zg.t-com.hr
15

16 Stela Bulimbašić - participated in collecting and analyzing data, stela.bulimbasic@gmail.com
17

18 Danica Galešić Ljubanović – participated in collecting and analyzing data,
19 danica.ljubanovic@zg.htnet.hr
20

21
22 Mirjana Sabljar Matovinović – participated in collecting data, mirjana.sabljar-
23 matovinovic@zg.t-com.hr
24

25
26 Mladen Knotek- proposed research design, analyzed data and participated in writing the paper,
27 mladen.knotek1@zg.t-com.hr
28
29
30
31
32

33
34 Support and Financial Disclosure Declaration:
35

36 Source of support: Grant by the Ministry of Science, Technology and Sports of the
37 Republic of Croatia to Dr. Mladen Knotek.
38

39
40 Disclosures:
41

42
43 The authors of this manuscript have no conflicts of interest to disclose.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Abbreviations:
4

5 IF/TA - interstitial fibrosis and tubular atrophy
6

7
8 MMF - mycophenolate mofetil
9

10 BK - polyoma virus BK
11

12 CNI - calcineurin inhibitors
13

14 DGF - delayed graft function
15

16 eCrCl - estimated creatine clearance
17

18 SPKT - simultaneous pancreas kidney transplantation
19

20 HLA MM – human leukocyte antigen mismatch
21

22 [AE - adverse events](#)
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT:

Objectives - Chronic transplant dysfunction after kidney transplantation is major reason of kidney graft loss and is caused by immunological and non-immunological factors.

There is evidence that mycophenolate mofetil (MMF) may exert a positive effect on renal damage in addition to immunosuppression, by its direct antifibrotic properties. The aim of our study was to retrospectively investigate role of MMF dose on progression of chronic allograft dysfunction and IF/TA.

Setting - Retrospective, cohort study.

Participants - Kidney transplant patients in tertiary care institution. This is a retrospective cohort study that included 79 patients with kidney and kidney-pancreas transplantation. Immunosuppression consisted of anti-IL2 antibody induction, MMF, a calcineurin inhibitor \pm steroids.

Primary outcome measures - An association of average MMF dose over 1 year post transplant with progression of interstitial fibrosis (Δ ci), tubular atrophy (Δ ct) and estimated creatinine clearance (eCrcl) at 1 year post transplant was evaluated using univariate and multivariate analyses.

Results - Higher average MMF dose was significantly independently associated with better eCrcl at 1 year post transplant ($b=0.21 \pm 0.1$, $p=0.04$). In multiple regression analysis lower Δ ci ($b=-0.2 \pm 0.09$, $p=0.05$) and Δ ct ($b=-0.29 \pm 0.1$, $p=0.02$) were independently associated with greater average MMF dose. There was no correlation between average MMF dose and incidence of acute rejection ($p=0.68$).

1
2
3 **Conclusions** - Higher average MMF dose over 1 year is associated with better renal
4 function and slower progression of IF/TA, at least partly independent of its
5
6 immunosuppressive effects.
7
8
9

10 11 12 **Strengths and limitations of this study**

13
14 Important novel finding in our study is that greater average MMF exposure was strongly
15 negatively correlated with IF/TA progression during first year after kidney
16 transplantation. Patients on higher average dose of MMF (up to 4 g daily) during 1 year
17 post transplantation had significantly lower progression of graft interstitial fibrosis and
18 tubular atrophy. This is important finding, because of predictive value of graft IF/TA and
19 should translate into better long-term graft survival. Our study has several shortcomings,
20 such as its retrospective aspect and relatively short study period. As it was not aim of the
21 study, we did not report side effects associated with different dosage of MMF.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 INTRODUCTION:
9

10
11
12 Kidney transplantation significantly improves patient survival and quality of life
13 comparing to dialysis. While significant improvements have been made in the treatment
14 of acute rejection and short survival of transplanted kidney, there has not been major
15 improvement in the long-term survival of transplanted kidney.[1] Chronic transplant
16 dysfunction after kidney transplantation is major cause of kidney graft loss and is evoked
17 by immunological and non-immunological factors.[2, 3] Histology changes that
18 determine chronic transplant dysfunction are interstitial fibrosis and tubular atrophy
19 (IF/TA), arteriosclerosis, arteriolar hyalinosis, glomerulopathy and mesangial matrix
20 expansion.[4] IF/TA is the major pathohistology finding that can be verified on graft
21 biopsies after kidney transplantation and is a predictor of long-term allograft function.[4]
22
23 Clinical factors that affect progression of IF/TA are: recipient age, HLA mismatch,
24 episodes of severe acute rejection, chronic rejection (esp. antibody-mediated), use of
25 calcineurin inhibitors and BK nephropathy. Avoidance of CNI toxicity is considered as
26 an important step to slow progression of IF/TA.[4-7] Mycophenolate mofetil (MMF) may
27 help lowering CNI toxicity, by allowing lower CNI exposure.[7]
28
29 MMF reduces the risk of acute allograft rejection, without nephrotoxic side effects and is
30 ideal candidate for long-term calcineurin drug reduction treatment strategies.[7]
31
32 Retrospective studies of renal recipients who were treated with mycophenolate mofetil
33 comparing azathioprin showed that MMF treated patients had significantly less chronic
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 allograft dysfunction.[8, 9] Besides being associated with lower acute rejection rates as
4 compared to azathioprin,[10, 11] evidence from animal and human studies suggests that
5
6 MMF may also exert a direct antifibrotic properties due to its antiproliferative action on
7
8 nonimmune cells, including renal tubular cells and vascular smooth muscle cells.[12, 13]
9
10
11
12 The aim of our study was to investigate role of mycophenolate mofetil dose on
13
14 progression of IF/TA in kidney transplant recipients.
15
16
17
18
19

20 PATIENTS AND METHODS:

21 *Patients:*

22
23
24
25
26
27 This is a retrospective study conducted at Clinical Hospital “Mercur”. This study
28
29 represents a part of the posttransplant immune monitoring at the Mercur hospital,
30
31 approved by the Hospital Ethics Committee. Patients gave there informed written consent for
32
33 anonymized transplant data collection for research purposes. The study included 79 patients
34
35 with kidney and kidney-pancreas transplantation, transplanted between 2003 and 2011.
36
37 Eligible patients had to have protocol kidney biopsy at the time of implantation and 12
38
39 months after transplantation. Exclusion criteria have been: dual kidney transplantation,
40
41 kidney-liver transplantation, use of antithymocyte immunoglobulin, BK nephropathy and
42
43 recurrence of glomerulonephritis after transplantation.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Immunosuppression:

Induction immunosuppression consisted of an anti-IL2 antibody (daclizumab or basiliximab), calcineurin inhibitor (tacrolimus or cyclosporine), MMF and methylprednisolone. Maintenance immunosuppression consisted of a calcineurin inhibitor (tacrolimus or cyclosporine), MMF ± steroids. Target cyclosporine trough concentrations were 250-350 during first month posttransplant, 200-300 during second to 6th month and 100-150 µg/L thereafter. Target tacrolimus trough levels were 10-12 during first month, 8-10 during second to 6th month and 5-8 µg/L thereafter. Mycophenolic acid target trough concentration was aimed to be higher than 7.2 µmol/L with tacrolimus and higher than 5 µmol/L with cyclosporine use.

Daclizumab was administered at day 0: 2mg/kg i.v. before opening of vascular anastomosis and at day 14: 2mg/kg i.v.. Basiliximab was administered at day 0: 20 mg i.v. before opening of vascular anastomosis and at day 4: 20 mg i.v..

Steroids have been dosed as follows: day 0: intraoperatively 500 mg of methylprednisolone, day 1: 250 mg, day 2: 125mg, day 3: 80 mg and day 4: 40 mg. In patients with early steroid withdrawal steroids have been withdrawn at day 5 after transplantation. In patients maintained on steroids, nadir dose of prednisone was 5 mg/d, achieved by 6 months. The criteria for early elimination of steroids were low immunological risk of the recipient (absence of, or low degree of HLA sensitization, i.e. PRA <10%) and good immediate renal function, as well as absence of an episode of acute rejection within 5 days after the transplantation. Steroids have been reintroduced in patients who suffered acute rejection episode.

1
2
3 As prophylaxis for viral (HSV, CMV), fungal (Candida spp.) urinary and P. jiroveci
4
5 infections, low-dose fluconazole (for one year), valganciclovir (universally for three
6
7 months) and sulfomethoxazol and trimethoprim (for one year) was used.
8
9
10

11
12
13
14
15
16
17
18
19
20 *Renal allograft biopsies:*

21
22 Protocol kidney biopsies were done at implantation, 1, 3, 6 and 12 months after
23
24 transplantation. For cause biopsies were done in case of unexplained deterioration of
25
26 renal function, or once weekly in patients with DGF. All rejection episodes were
27
28 histologically confirmed. Histopathological analysis was performed by either of two
29
30 pathologists who were blinded for immunosuppression. Acute rejections and chronic
31
32 allograft scores have been analyzed using Banff 97 classification and its updates.[14, 15]
33
34

35
36 All protocol and indication biopsies were analyzed by light microscopy, by
37
38 immunofluorescence for C4d, and if indicated by immunohistochemistry for BK virus.
39
40 Biopsies at 1 year post transplant have been also analyzed by electron microscopy for
41
42 signs of chronic antibody-mediated rejection (transplant glomerulopathy, peritubular
43
44 capillary basement membrane multilayering).[16]
45
46
47
48
49

50
51 *Clinical outcome parameters:*

52
53 Progression of chronic allograft scores during 1 year posttransplant was calculated by
54
55 subtracting implantation chronic scores from chronic allograft scores 12 months
56
57
58
59
60

1
2
3 posttransplant: interstitial fibrosis (Δci), tubular atrophy (Δct), glomerulosclerosis (Δcg),
4
5 mesangial matrix increase (Δmm), vasculopathy (Δcv) and arteriolar hyalinosis (Δah).
6
7

8 Estimated creatinine clearance (eCr_{cl}) at 3, 6 and 12 months posttransplant was calculated
9
10 using Cockcroft-Gault formula. Acute rejections with Banff grade IA and IB were treated
11
12 with three 500 mg methylprednisolone pulses. In case of acute rejection grade IIA or
13
14 greater, patients have been treated with antithymocyte globulin. Antibody-mediated
15
16 rejections were treated with steroid pulse and plasmapheresis.
17
18

19
20 Average dose of MMF during 1 year posttransplant was calculated from MMF dose at
21
22 month 1, 3, 6 and 12.
23

24 Adverse effects analysed were clinically significant leucopenia, defined as white blood
25
26 cell count less than 3000/ml, time to first symptomatic infection and number of
27
28 symptomatic infection episodes per patient during first post transplant year.
29
30
31

32
33
34 *Statistical analysis:*
35

36 Numerical data are presented as mean \pm SD or median with range in case of not normal
37
38 distribution. Normality of distribution has been tested with Kolmogorov-Smirnov test.
39
40 Correlation between two continuous variables has been tested using Spearman
41
42 nonparametric correlation. Difference between two groups in continuous variables has
43
44 been tested with student t-test or with Mann–Whitney test in non-normally distributed
45
46 variables. The significance of the progression in chronic scores was analyzed using
47
48 Wilcoxon Matched Pairs test. Univariate and multiple linear regression analysis were
49
50 performed to determine predictive factors for progression of chronic allograft scores and
51
52 kidney function at 12 months after transplantation. All variables that were associated with
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

respective outcome in bivariate analysis (at $p \leq 0.1$) were included in multivariate analysis. Because of colinearity between ci and ct score, only one score was included in each multivariate analysis. Statistical significance was considered at $p < 0.05$. All statistical analyses were performed using Statistica 10 (StatSoft, Tulsa, OK, USA).

RESULTS:

Patient and transplant characteristics:

Patient characteristics are shown in Table 1. Recipients were a mean of 44.67 ± 12.03 years old at the time of transplantation, 68 percent of them were male and all were Caucasians. 33 percent of recipients had DGF after transplantation. Donors were a mean of 43.89 ± 15.55 years old and 54 percent of them were male. Number of living donor transplantations was 24 (30 percent). Average daily MMF dose during 1 year posttransplant was 2244 ± 585 mg (1062 – 4000) (Table 25). As expected, there was no correlation of MMF dose with MMF trough concentration ($R = -0.13$; $p = 0.28$). Also, there was no correlation between MMF dose with tacrolimus concentration ($R = -0.04$; $p = 0.79$). Early steroid withdrawal was done in 46 percent of patients after transplantation. Incidence of subclinical and clinical acute rejections greater than borderline was 30 percent in first year. There was no correlation between average MMF dose and incidence of acute rejection ($p = 0.68$).

Factors associating with eCr_{cl}:

Kidney function increased during 1st year post transplant. eCr_{cl} at month 3 was 56.98 ± 15.78 ml/min, at 6 month 58.94 ± 16.94 ml/min and at 12 month 61.47 ± 16.75 ml/min ($p < 0.001$; 12 months vs. 3 months) (Figure 1.) eCr_{cl} at 1 year post transplant was greater in SPKT recipients (71.38 ± 13.45 ml/min vs. 57.88 ± 16.47 ml/min; $p = 0.001$) and in patients who did not have DGF (64.08 ± 15.87 ml/min vs. 56.15 ± 17.55 ml/min; $p = 0.05$). Donor age ($R = -0.46$; $p < 0.001$) and recipient age ($R = -0.46$; $p < 0.001$) negatively correlated with eCr_{cl} at 1 year post transplant, while there was no correlation of renal function with donor and recipient gender, type of donation (deceased vs. living), HLA MM, average CNI concentration, steroid-free regimen of immunosuppression, or history of acute rejection (Table 36). In univariate analysis allograft function at 12 month post Tx was also negatively correlated with ci ($R = -0.34$; $p = 0.002$) and ct ($R = -0.35$; $p = 0.002$) at 12 month (Figure 212A, Figure 212B). Although MMF dose was positively correlated with renal function with borderline significance in univariate analysis, in multivariate analysis there was a significant positive association between greater average MMF dose and better eCr_{cl} at 12 month post transplant ($b = 0.21 \pm 0.1$; $p = 0.04$) (Table 42).

Factors affecting IF/TA:

The average ci score increased from 0.16 ± 0.44 to 0.94 ± 0.86 between implantation and month 12 ($p < 0.001$). Average progression of this and other chronic scores during 1 year post transplant is shown in ~~suppl. data~~ (Table 57). In univariate analysis Δci ($R = -0.37$; $p = 0.001$) and Δct ($R = -0.38$; $p = 0.001$) significantly negatively correlated with average MMF dose (Figure 323A and 323B, Table 63). There was lower progression of ci score

1
2
3 in patients on steroid-free immunosuppression (0.47 ± 0.7 vs. 1.09 ± 0.87 ; $p=0.002$) and
4
5 in those who did not have DGF (0.62 ± 0.74 vs 1.19 ± 0.98 ; $p=0.02$). Acute cellular
6
7 rejection, recipient and donor gender, recipient and donor age, HLA MM, deceased vs.
8
9 living donor, as well as average concentration of tacrolimus had no significant effect on
10
11 progression of chronic allograft scores. Factors that remained significantly associated
12
13 with progression of ci score in multivariate analysis were ci0 score, donor age, average
14
15 MMF dose, DGF and steroid-free immunosuppression (Table 74.). In multivariate
16
17 analysis only ct0 score, average MMF dose and DGF remained independently associated
18
19 with 12-month progression of ct score (Table 74.). Selected AE are shown in Table 8.
20
21 There was no difference in AE (leucopenia and infections) with respect to average
22
23 median MMF dose.
24
25
26
27
28
29

30 31 Discussion:

32
33
34
35
36 The most important novel finding in our study is that greater average MMF exposure was
37
38 strongly negatively correlated with IF/TA progression during first year after kidney
39
40 transplantation. Patients on higher average dose of MMF during 1 year post
41
42 transplantation had significantly lower progression of ci and ct scores. To our knowledge
43
44 this is first study demonstrating that there is a dose-dependent protective effect of MMF
45
46 on graft IF/TA. Lower progression of IF/TA could not be explained with lower
47
48 concentration of CNI, because there was not correlation between tacrolimus
49
50 concentration with IF/TA. Similarly, there was no correlation between average MMF
51
52 dose and tacrolimus ($R=-0.04$; $p=0.79$) or cyclosporine concentration ($R=-0.07$, $p=0.79$).
53
54
55
56
57
58
59
60

1
2
3 In addition, higher average MMF dose was not associated with decreased incidence of
4 biopsy proven acute rejection, which suggests that antifibrotic properties of higher MMF
5 dose was at least partly independent of its immunosuppressive effects. Higher MMF dose
6 had only moderate effect on 1-year renal function, which is consistent with previous
7 reports showing that transplanted kidneys undergo pathohistology changes without
8 significant early change in kidney function.[17]

9
10 In the present retrospective study we have confirmed that IF/TA progression occurs in
11 first year after kidney transplantation. Several studies have shown that progression of
12 IF/TA is correlated with type of immunosuppression.[18] In most transplant centers in
13 the United States and Europe immunosuppression consists of induction with an anti-IL2R
14 antibody or antithymocyte immunoglobulin and maintenance with a calcineurin inhibitor,
15 MMF and steroids.[19] Studies have reported significant improvement in kidney function
16 in patients on MMF with lower exposition to CNIs, esp. tacrolimus.[20] Recently, in the
17 paper of Kamar *et al.* it has been reported that maintenance kidney transplant patients
18 converted to a higher dose of the mycophenolate sodium (1440 mg daily) with lower
19 tacrolimus concentration had borderline higher eCr_{cl} on month 6 vs. those treated with
20 lower dose of mycophenolate sodium, with usual tacrolimus concentration (eCr_{cl} 49.1 ±
21 11.1 vs. 44.7 ± 11.5 ml/min; p=0.07).[21] Although there was only borderline
22 significance, increased mycophenolate dosing with lower tacrolimus concentration was
23 safe with potential benefit on kidney function.

24
25 Our study also corroborates recently published findings of a *post hoc* joint analysis of the
26 Symphony, FDCC and OptiCept trials, where a a lower tacrolimus level and a higher
27 MMF dose were associated with significantly better kidney function at 1 year post
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 transplant.[22] Shortcoming of these studies[17,18] is lack of protocol biopsies. The
4
5 optimal MMF dosing in patients maintained on contemporary low-dose CNI is still
6
7 undetermined. However, some results of early MMF registration trials suggest that higher
8
9 MMF exposure might be beneficial; having in mind that there was no antibody induction
10
11 in these studies and that CNI was standard dose cyclosporine. Thus, in the Tri-continental
12
13 study, group treated with 3 g MMF compared with 2 g of MMF showed lower incidence
14
15 of biopsy proven acute rejection episodes (15.9% vs. 19.7%) within 6 month period
16
17 selected for the primary efficacy analysis. Similarly, serum creatinine level at 1 year was
18
19 1.42 ± 0.07 mg/dL in the MMF 3 g group vs. 1.64 ± 0.07 mg/dL in MMF 2 g group.[12]
20
21 In the European mycophenolate mofetil study same trends regarding higher MMF dose
22
23 were observed.[11] As mentioned before, in these studies there was no antibody
24
25 induction that could have allowed lower dose of cyclosporin with higher dose of MMF
26
27 and there were no protocol biopsies. In a more recent MYSS trial, there was no difference
28
29 in acute rejection rate and renal function between MMF and azathioprine in a
30
31 cyclosporine-based protocol.[19] However in that study only one MMF dose was
32
33 compared to azathioprine[23] and again there were no protocol biopsies.
34
35 Unfortunately adequate prospective MMF dose comparison studies in tacrolimus-based
36
37 protocols with antibody induction are missing. In the Symphony study it was reported
38
39 that patients on tacrolimus-MMF-prednisone maintenance immunosuppression after kidney
40
41 transplantation had better kidney function and graft survival with lower number of acute
42
43 rejection episodes. Patients in that group had highest MMF exposure.[24] Protocols with
44
45 even higher MMF exposure might allow additional CNI sparing, that would decrease side
46
47 effect of CNI (hypertension, diabetes, hyperlipidemia, neurotoxicity).[25]
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Clinical relevance of IF/TA without other concomitant pathology (i.e. recurrent disease
4 and chronic antibody-mediated rejection) for prediction of graft deterioration and loss is
5 controversial. In El-Zoghby et al. study there was attempt to identify specific causes of
6 late kidney allograft failure. The authors found that transplant glomerulopathy was
7 responsible for 37 percent loss of functioning grafts, while graft loss due to IF/TA was
8 present in 31 percent of cases (with higher frequency in deceased-donor transplants).[26]

9
10
11
12
13
14
15
16
17 At first glance, these results seem at odd with ours, where there were no signs of chronic
18 antibody-mediated rejection. An explanation for this discrepancy in the results of the two
19 studies is not completely clear, but the former study included high number of living
20 transplants (72.5 percent) with glomerulonephritis as primary disease and with follow-up
21 up to 10 years. Transplant glomerulopathy is more frequently seen late posttransplant,
22 generally with low incidence. Nevertheless, ours and El-Zoghby study, both
23 demonstrated that IF/TA even in absence of other pathology is associated with adverse
24 graft outcome. Another important study, the DeKaf study, tried to use various
25 histopathologic clusters to differentiate subgroups within diagnosis of IF/TA. They found
26 that cluster with more severe fibrosis plus inflammation and arterial lesions had the worst
27 prognosis.[27] Although incidence of acute rejection in our study did not vary with MMF
28 exposure, increased MMF exposure might suppress mild graft inflammation, below the
29 threshold for diagnosing acute rejection. This is subject of our ongoing investigation and
30 will be reported separately. An interesting finding of the present study was that early
31 steroid withdrawal was not associated with worse IF/TA. At first glance this is at odd
32 with the Astellas trial.[23] However, according to our protocol, patients with DGF were
33 not included in early steroid withdrawal and Astellas trial, which did not have protocol

1
2
3 biopsies, reported increased IF/TA in early steroid withdrawal group based on indication
4
5 biopsies performed early posttransplant, thus more likely reflecting donor-derived
6
7
8 histology changes, rather than effect of steroid withdrawal.[28]
9

10
11 In our study there was only borderline significance of positive association of 1-year eCr_{cl}
12
13 with MMF in univariate analysis. This result is not very surprising since decreased renal
14
15 function is not a very sensitive marker of incipient IF/TA.
16

17
18 Mechanisms by which an average higher exposure to MMF was associated with slower
19
20 progression of IF/TA may be both immune and nonimmune. Because there was no
21
22 difference in incidence of acute rejection with respect to increased MMF exposure in our
23
24 study, we believe that there may be a significant contribution of nonimmune mechanisms
25
26 in retardation of IF/TA in patients with higher MMF. In line with this, in many
27
28 experimental models it has been shown that MMF has antiproliferative and antifibrotic
29
30 effect.[29-31] In the study of Jiang at al. using rat renal ischemia reperfusion injury, a
31
32 time- and dose-dependent correlation of higher MMF dose with better renal function and
33
34 lower interstitial fibrosis was demonstrated. Suggested potential mechanism was lower
35
36 expression of TGF- β 1 and MCP-1 with lower macrophage infiltration.[32] In recent
37
38 clinical trials MMF was shown as a safe drug that could be a good candidate for
39
40 treatment of interstitial lung disease in systemic sclerosis.[33] Experimental model of
41
42 encapsulated peritoneal sclerosis in rats proved beneficial effect of MMF as an inhibitor
43
44 of neovascularisation.[34] Also, MMF monotherapy was associated with a positive effect
45
46 on hepatic fibrosis progression in HCV liver transplant recipients.[35]
47
48
49
50

51
52 Our study has several shortcomings, such as its retrospective aspect and relatively short
53
54 study period. Although study period was limited to 12 months post transplantation, a
55
56
57
58
59
60

1
2
3 clear correlation of slower progression of IF/TA with higher average MMF dose
4
5 underlines potential benefit of these findings. As mentioned before, in current study we
6
7 did not analyze inflammation outside Banff acute rejection threshold in kidney biopsies
8
9 with respect to MMF dose. As inflammation in areas of IF/TA is an important predictor
10
11 of renal function and graft loss, this is subject of an ongoing work.
12
13

14
15 In summary, higher MMF dose after kidney transplantation might slow progression of
16
17 IF/TA, which might lead to better long-term survival of transplanted kidney. Our study

18
19 may serve as a platform for a prospective, randomized, long-term trial with different
20
21 MMF doses to evaluate benefit of higher MMF dose in renal transplant recipients
22
23 [\(NCT018600183\)](#).
24
25
26
27

28 29 Acknowledgments:

30
31 This manuscript has not been published elsewhere, beside as a part of 2011 ASN Annual
32
33 meeting abstract.
34
35
36
37
38

39 [Figure 1: Estimated creatinine clearance during first year posttransplant](#)

40
41 [Figure 2A: Correlation between average MMF dose and progression of ci score](#)

42
43 [Figure 2B: Correlation between average MMF dose and progression of ct score](#)

44
45 [Figure 3A: Estimated creatinine clearance by ci score](#)

46
47 [Figure 3B: Estimated creatinine clearance by ct score](#)
48
49
50
51
52
53
54
55
56
57
58
59
60

Reference List

- 1 Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. *N Engl J Med* 2002; 346:580-590.
- 2 Kuypers DR, Chapman JR, O'Connell PJ et al. Predictors of renal transplant histology at three months. *Transplantation* 1999; 67:1222-1230.
- 3 Matas AJ, Gillingham KJ, Payne WD et al. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). *Transplantation* 1994;57:857-859.
- 4 Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. *N Engl J Med* 2003; 349:2326-2333.
- 5 Birnbaum LM, Lipman M, Paraskevas S et al. Management of chronic allograft nephropathy: a systematic review. *Clin J Am Soc Nephrol* 2009; 4:860-865.
- 6 Frimat L, Cassuto-Viguiet E, Charpentier B et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. *Am J Transplant* 2006; 6:2725-2734.
- 7 Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. *N Engl J Med* 2007; 357:2562-2575.
- 8 Azuma H, Binder J, Heemann U et al. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. *Transplantation* 1995; 59:460-466.
- 9 Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. *Transplantation* 2000; 69:2405-2409.
- 10 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. *Transplantation* 1996; 61:722-729.
- 11 European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. *Lancet* 1995; 345, 1321-1325.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 12 Djamali A, Vidyasagar A, Yagci G et al. Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway. *Transplantation* 2010;90:387-393.
 - 13 Dell'Oglio MP, Zaza G, Rossini M et al. The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. *J Am Soc Nephrol* 2010; 21:2157-2168.
 - 14 Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. *Am J Transplant* 2008; 8:753-760.
 - 15 Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. *Kidney Int* 1999; 55:713-723.
 - 16 Roufosse CA, Shore I, Moss J et al. Peritubular capillary basement membrane multilayering on electron microscopy: a useful marker of early chronic antibody-mediated damage. *Transplantation* 2012; 94:269-274.
 - 17 Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. *N Engl J Med* 2003; 349:2326-2333.
 - 18 Gelens MA, Steegh FM, van Hooff JP et al. Immunosuppressive Regimen and Interstitial Fibrosis and Tubules Atrophy at 12 Months Postrenal Transplant. *Clin J Am Soc Nephrol* 2012; 5:1010-1017.
 - 19 Available at:
http://srtr.transplant.hrsa.gov/annual_reports/2011/pdf/01_kidney_12.pdf. 2013.
 - 20 Ekberg H, van GT, Kaplan B et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. *Transplantation* 2011; 92:82-87.
 - 21 Kamar N, Rostaing L, Cassuto E et al. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. *Clin Nephrol* 2012 ;77:126-136.
 - 22 Ekberg H, van GT, Kaplan B et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. *Transplantation* 2011; 92:82-87.
 - 23 Remuzzi G, Lesti M, Gotti E et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. *Lancet* 2004; 364:503-512.
 - 24 Lloberas N, Torras J, Cruzado JM et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic

- 1
2
3 Substudy within the Symphony Study. *Nephrol Dial Transplant* 2011; 26:3784-
4 3793.
5
6
7 25 Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes
8 after renal transplantation. *N Engl J Med* 2002; 346:580-590.
9
10 26 El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney
11 allograft loss. *Am J Transplant* 2009;9:527-535.
12
13 27 Matas AJ, Leduc R, Rush D et al. Histopathologic clusters differentiate subgroups
14 within the nonspecific diagnoses of CAN or CR: preliminary data from the
15 DeKAF study. *Am J Transplant* 2010; 10:315-323.
16
17
18 28 Woodle ES, First MR, Pirsch J et al. A prospective, randomized, double-blind,
19 placebo-controlled multicenter trial comparing early (7 day) corticosteroid
20 cessation versus long-term, low-dose corticosteroid therapy. *Ann Surg*; 248: 564-
21 577.
22
23
24 29 Luo L, Sun Z, Wu W et al. Mycophenolate mofetil and FK506 have different
25 effects on kidney allograft fibrosis in rats that underwent chronic allograft
26 nephropathy. *BMC Nephrol* 2012;13:53.
27
28
29 30 Jiang S, Tang Q, Rong R et al. Mycophenolate mofetil inhibits macrophage
30 infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. *Eur J*
31 *Pharmacol* 2012; 688:56-61.
32
33 31 Dell'Oglio MP, Zaza G, Rossini M et al. The anti-fibrotic effect of mycophenolic
34 acid-induced neutral endopeptidase. *J Am Soc Nephrol* 2010; 21:2157-2168.
35
36
37 32 Jiang S, Tang Q, Rong R et al. Mycophenolate mofetil inhibits macrophage
38 infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. *Eur J*
39 *Pharmacol* 2012; 688:56-61.
40
41 33 Tzouveleakis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntoliou P, et al.
42 Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-
43 associated interstitial lung disease: a meta-analysis. *Pulm Med* 2012; 1-7.
44
45
46 34 Hur E, Bozkurt D, Timur O, Bicak S, Sarsik B, Akcicek F, et al. The effects of
47 mycophenolate mofetil on encapsulated peritoneal sclerosis model in rats. *Clin*
48 *Nephrol* 2012; 77:1-7.
49
50 35 Manzia TM, Angelico R, Toti L et al. Long-term, maintenance MMF
51 monotherapy improves the fibrosis progression in liver transplant recipients with
52 recurrent hepatitis C. *Transpl Int* 2011; 24:461-468.
53
54
55
56
57
58
59
60

Table 1. Baseline characteristics

RECIPIENT CHARACTERISTICS	AGE (years)	44.67 ± 12.03
	GENDER (f/m)	25/54
	PRIMARY RENAL DISEASE (diabetes mellitus, polycystic kidney disease, glomerulonephritis, pyelonephritis/interstitial nephritis, other/unknown)	24/8/19/6/22
DONOR CHARACTERISTICS	DONOR SOURCE (deceased/living)	55/24
	AGE (years)	43.89 ± 15.55
	GENDER (f/m)	36/43
TRANSPLANTATION CHARACTERISTICS	TRANSPLANTED ORGAN (KIDNEY/SPKT)	58/21
	INITIAL IMMUNOSUPPRESSION (anti-IL2,TAC,MMF/anti-IL2, CyA,MMF)	53/26
	DELAYED GRAFT FUNCTION (no/yes)	53/26
	STEROID FREE (yes/no)	36/43
	HLA MM	3.33 ± 1.51

Table 2. eCr_{cl}, MMF dose and CNI concentration during first year post transplant

	Month posttransplant			
	1	3	6	12
eCr _{cl} (ml/min)		56.98 ± 15.79	58.94 ± 16.94	61.47 ± 16.75
MMF dose (mg)	2500 (750 – 4000) 2427 ± 643.17	2000 (750 – 4000) 2167.72 ± 733.49	2000 (1000-4000) 2188.29 ± 716.91	2000 (1000-4000) 2193.04 ± 642.95
Tacrolimus conc. (µg/L) (n=53)	10.79 ± 4.16	9.69 ± 3.00	9.03 ± 5.52	7.83 ± 2.45
Cyclosporin conc. (µg/L) (n=26)	335.07 (274 – 413)	231.05 (181-265)	206 (170 – 257)	131 (125 – 171)

Table 3. Association of variables with eCr_{cl} on 1 year

	Estimated creatinine clearance (ml/min)	p value
Kidney vs. SPKT	57.88 ± 15.47 vs. 71.38 ± 13.45	0.001
DGF (yes vs. no)	56.15 ± 17.55 vs. 64.08 ± 15.87	0.05
Recipient gender (m vs. f)	59.83 ± 16.02 vs. 65 ± 18.07	0.2
Donor gender (m vs. f)	63.87 ± 16.71 vs. 58.60 ± 16.58	0.17
Donor source (D vs. L)	62.36 ± 17.85 vs. 59.43 ± 14.05	0.47
Steroid-free (yes vs. no)	63.94 ± 17.73 vs. 59.39 ± 15.81	0.23
Acute rejection (yes vs. no)	61.64 ± 16.59 vs. 61.39 ± 16.97	0.95
	R	p value
Recipient age	-0.45	<0.001
Donor age	-0.46	<0.001
HLA MM	0.07	0.52
Average tacrolimus concentration	-0.02	0.9
Average MMF dose	0.18	0.1
ci at 1 year post Tx	-0.34	0.002
ct at 1 year post Tx	-0.35	0.002
cv at 1 year post Tx	-0.20	0.07

Table 4. Multiple regression analysis of factors associated with kidney function

	Beta (β)	St.Err. β	p value
Tx (kidney)	-0.17	0.13	0.19
DGF (no)	0.04	0.1	0.71
Recipient age	-0.41	0.1	<0.001
Donor age	-0.1	0.14	0.45
ci at 12 months	-0.18	0.11	0.09
Average MMF dose	0.21	0.1	0.04

Table 5. One-year progression of chronic allograft scores

Banff score	N	At transplantation	N	12 month	p
Interstitial fibrosis (ci)	79	0.16 ± 0.44	79	0.94 ± 0.85	<0.001
Tubular atrophy (ct)	79	0.24 ± 0.46	79	1.05 ± 0.77	<0.001
Chronic glomerulopathy (cg)	79	0	79	0	
Mesangial matrix (mm)	79	0.01 ± 0.11	79	0.09 ± 0.36	0.09
Fibrointimal thickening (cv)	76	0.37 ± 0.83	78	0.29 ± 0.70	0.47
Arteriolar hyalinosis (ah)	78	0.68 ± 1.04	79	0.79 ± 1.04	0.26

Table 6. Correlation of factors associated with progression of ci and ct scores

	Δ ci		Δ ct	
	mean \pm SD	p	mean \pm SD	p
Kidney vs. SPKT	0.86 \pm 0.91 vs. 0.67 \pm 0.73	0.51	0.85 \pm 0.87 vs. 0.86 \pm 0.65	0.74
DGF (yes vs. no)	1.19 \pm 0.98 vs. 0.62 \pm 0.74	0.02	1.15 \pm 0.92 vs. 0.69 \pm 0.72	0.05
Recipient gender (m vs. f)	0.83 \pm 0.88 vs. 0.76 \pm 0.83	0.78	0.91 \pm 0.83 vs. 0.72 \pm 0.79	0.35
Donor gender (m vs. f)	0.91 \pm 0.95 vs. 0.69 \pm 0.75	0.43	0.88 \pm 0.93 vs. 0.81 \pm 0.67	0.96
Donor source (D vs. L)	0.84 \pm 0.88 vs. 0.75 \pm 0.85	0.73	0.87 \pm 0.82 vs. 0.79 \pm 0.83	0.71
Steroid free (yes vs. no)	1.09 \pm 0.87 vs. 0.47 \pm 0.74	0.002	1.07 \pm 0.83 vs. 0.58 \pm 0.73	0.01
Acute rejection (yes vs. no)	0.8 \pm 0.89 vs. 0.83 \pm 0.82	0.78	0.93 \pm 0.84 vs. 0.67 \pm 0.76	0.23
	R	p	R	p
Recipient age	-0.11	0.33	-0.11	0.32
Donor age	0.17	0.13	0.04	0.73
HLA MM	-0.09	0.43	-0.002	0.99
Average tacrolimus conc.	-0.009	0.95	0.003	0.98
Average MMF dose	-0.37	<0.001	-0.38	<0.001
ci at implantation	-0.32	0.003		
ct at implantation			-0.45	<0.001

Table 7. Multivariate general regression analysis for factors related to progression of ci and ct score


Δci			
	Beta (β)	Std. Err. β	p
ci0	-0.43	0.09	<0.001
DGF (no)	-0.22	0.11	<0.05
Average MMF dose	-0.20	0.09	<0.05
Donor age	0.32	0.09	<0.05
Steroid free (yes)	-0.25	0.11	0.02
Δct			
	Beta (β)	Std. Err. β	p
ct0	-0.44	0.09	<0.001
Average MMF dose	-0.29	0.1	<0.05
DGF (no)	-0.29	0.1	<0.05
Steroid free (yes)	-0.09	0.11	0.39

Table 8. Adverse events with respect to 1 year average median MMF dose.

	<u>MMF dose < median</u>	<u>MMF dose > median</u>	<u>p</u>
<u>Average number of infection episodes per patient</u>	<u>1.16 ± 0.97</u>	<u>1.23 ± 1.22</u>	<u>0.88</u>
<u>Mean time to first infection (days)</u>	<u>157±138</u>	<u>175±143</u>	<u>0.76</u>
<u>Proportion of patients with leucopenia</u>	<u>6 /31</u>	<u>7 /48</u>	<u>0.58</u>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 1: Estimated creatinine clearance during first year posttransplant



*, $p < 0.001$; 3 month vs. 12 months eCrCl. Values are shown as mean \pm SD

90x105mm (300 x 300 DPI)


Figure 2A: Correlation between average MMF dose and progression of ci score



90x121mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 2B: Correlation between average MMF dose and progression of ct score



90x121mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3A: Estimated creatinine clearance by ci score



* $p < 0.05$; score ci 0 vs. score ci 3 (*post hoc* Newman-Keuls test)


** $p = 0.03$; score ci 1 vs. score ci 3

Values are shown as mean \pm SD

90x121mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3B: Estimated creatinine clearance by ct score



* $p < 0.05$; score ct 0 vs. score ct 3 (post hoc Newman-Keuls test)

** $p = 0.03$; score ct 1 vs. score ct 3

Values are shown as mean \pm SD

90x121mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No/page number	Recommendation
Title and abstract	1/1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2/5	Explain the scientific background and rationale for the investigation being reported
Objectives	3/5,6	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4/6	Present key elements of study design early in the paper
Setting	5/6,7,8,9	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6/6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7/6,7,8	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/measurement	8*/8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10/6	Explain how the study size was arrived at
Quantitative variables	11/9	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12/9	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

Results

Participants	13* /9, 10	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14* /9, 10	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15* /11	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16/ 10, 11	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18/ 12	Summarise key results with reference to study objectives
Limitations	19/ 16	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20/ 12- 16	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21/ 12- 16	Discuss the generalisability (external validity) of the study results

Other information

Funding	22/ 2	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----------	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Effect of Mycophenolate Mofetil on Progression of Interstitial Fibrosis and Tubular Atrophy after Kidney Transplantation- A Retrospective Study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005005.R2
Article Type:	Research
Date Submitted by the Author:	06-Jun-2014
Complete List of Authors:	Mihovilovic, Karlo; University Hospital Merkur, Division of nephrology Maksimovic, Bojana; University Hospital Merkur, Division of nephrology Kocman, Branislav; University Hospital Merkur, Department of surgery Gustin, Denis; University hospital Merkur, Department of anesthesiology Vidas, Zeljko; University Hospital Merkur, Department of urology Bulimbasic, Stela; University Hospital Dubrava, Department of pathology Ljubanovic, Danica; University Hospital Dubrava, Department of pathology Matovinovic, Mirjana; University Hospital Merkur, Division of nephrology Knotek, Mladen; University Hospital Merkur, Division of nephrology
Primary Subject Heading:	Renal medicine
Secondary Subject Heading:	Pharmacology and therapeutics, Renal medicine, Pathology
Keywords:	Histopathology < PATHOLOGY, TRANSPLANT MEDICINE, Renal transplantation < NEPHROLOGY

SCHOLARONE™
Manuscripts

only

1

2
3
4 **Effect of Mycophenolate Mofetil on Progression of Interstitial Fibrosis and Tubular**
5
6 **Atrophy after Kidney Transplantation - A Retrospective Study**
7
8

9
10 Karlo Mihovilović¹, Bojana Maksimović¹, Branislav Kocman², Denis Guštin³, Željko Vidas⁴,
11 Stela Bulimbašić⁶, Danica Galešić Ljubanović^{5,6}, Mirjana Sabljar Matovinović¹, Mladen
12 Knotek^{1,5}
13
14
15
16

17
18 Clinical Hospital Merkur: ¹ Department of Medicine, Renal Division, ² Department of Surgery,
19
20 ³ Department of Anaesthesiology, ⁴ Department of Urology; ⁵ University of Zagreb School of
21
22 Medicine, Zagreb, Croatia, Clinical Hospital Dubrava: ⁶ Department of Pathology
23
24
25
26

27 **Keywords:** interstitial fibrosis, tubular atrophy, kidney function, myophenolate mofetil
28

29 Word count: Abstract-238
30

31 Manuscript- 3049
32

33 **Number of tables: 8**
34

35 **Number of figures: 3**
36

37 **Corresponding author:** Dr. Mladen Knotek
38

39 Department of Medicine, Renal Division
40

41 Clinical Hospital Merkur
42

43 Zajceva 19
44

45 10000 Zagreb
46

47 Croatia
48

49 e-mail: mladen.knotek1@zg.t-com.hr (this e-mail address can be published)
50

51 phone: +38512431123, fax: +38512431123
52
53
54
55
56
57
58
59
60

2

ABSTRACT:

Objectives - Chronic transplant dysfunction after kidney transplantation is major reason of kidney graft loss and is caused by immunological and non-immunological factors.

There is evidence that mycophenolate mofetil (MMF) may exert a positive effect on renal damage in addition to immunosuppression, by its direct antifibrotic properties. The aim of our study was to retrospectively investigate role of MMF dose on progression of chronic allograft dysfunction and IF/TA.

Setting - Retrospective, cohort study.

Participants - Kidney transplant patients in tertiary care institution. This is a retrospective cohort study that included 79 patients with kidney and kidney-pancreas transplantation. Immunosuppression consisted of anti-IL2 antibody induction, MMF, a calcineurin inhibitor \pm steroids.

Primary outcome measures - An association of average MMF dose over 1 year post transplant with progression of interstitial fibrosis (Δ ci), tubular atrophy (Δ ct) and estimated creatinine clearance (eCrcl) at 1 year post transplant was evaluated using univariate and multivariate analyses.

Results - Higher average MMF dose was significantly independently associated with better eCrcl at 1 year post transplant ($b=0.21 \pm 0.1$, $p=0.04$). In multiple regression analysis lower Δ ci ($b=-0.2 \pm 0.09$, $p=0.05$) and Δ ct ($b=-0.29 \pm 0.1$, $p=0.02$) were independently associated with greater average MMF dose. There was no correlation between average MMF dose and incidence of acute rejection ($p=0.68$).

Conclusions - Higher average MMF dose over 1 year is associated with better renal function and slower progression of IF/TA, at least partly independent of its immunosuppressive effects.

Strengths and limitations of this study

1
2
3
4
5 Important novel finding in our study is that greater average MMF exposure was strongly
6 negatively correlated with IF/TA progression during first year after kidney
7 transplantation. Patients on higher average dose of MMF (up to 4 g daily) during 1 year
8 post transplantation had significantly lower progression of graft interstitial fibrosis and
9 tubular atrophy. This is important finding, because of predictive value of graft IF/TA and
10 should translate into better long-term graft survival. Our study has several shortcomings,
11 such as its retrospective aspect and relatively short study period. As it was not aim of the
12 study, we did not report side effects associated with different dosage of MMF.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **INTRODUCTION:**

42
43 Kidney transplantation significantly improves patient survival and quality of life
44 comparing to dialysis. While significant improvements have been made in the treatment
45 of acute rejection and short survival of transplanted kidney, there has not been major
46 improvement in the long-term survival of transplanted kidney.[1] Chronic transplant
47 dysfunction after kidney transplantation is major cause of kidney graft loss and is evoked
48 by immunological and non-immunological factors.[2, 3] Histology changes that
49 determine chronic transplant dysfunction are interstitial fibrosis and tubular atrophy
50
51
52
53
54
55
56
57
58
59
60

(IF/TA), arteriosclerosis, arteriolar hyalinosis, glomerulopathy and mesangial matrix expansion.[4] IF/TA is the major pathohistology finding that can be verified on graft biopsies after kidney transplantation and is a predictor of long-term allograft function.[4] Clinical factors that affect progression of IF/TA are: recipient age, HLA mismatch, episodes of severe acute rejection, chronic rejection (esp. antibody-mediated), use of calcineurin inhibitors and BK nephropathy. Avoidance of CNI toxicity is considered as an important step to slow progression of IF/TA.[4-7] Mycophenolate mofetil (MMF) may help lowering CNI toxicity, by allowing lower CNI exposure.[7] MMF reduces the risk of acute allograft rejection, without nephrotoxic side effects and is ideal candidate for long-term calcineurin drug reduction treatment strategies.[7] Retrospective studies of renal recipients who were treated with mycophenolate mofetil comparing azathioprin showed that MMF treated patients had significantly less chronic allograft dysfunction.[8, 9] Besides being associated with lower acute rejection rates as compared to azathioprin,[10, 11] evidence from animal and human studies suggests that MMF may also exert a direct antifibrotic properties due to its antiproliferative action on nonimmune cells, including renal tubular cells and vascular smooth muscle cells.[12, 13] The aim of our study was to investigate role of mycophenolate mofetil dose on progression of IF/TA in kidney transplant recipients.

PATIENTS AND METHODS:

Patients:

This is a retrospective study conducted at Clinical Hospital “Mercur”. This study represents a part of the posttransplant immune monitoring at the Mercur hospital, approved by the Hospital Ethics Committee. Patients gave there informed written consent for anonymized transplant data collection for research purposes. The study included 79 patients

1
2
3
4 with kidney and kidney-pancreas transplantation, transplanted between 2003 and 2011.
5
6 Eligible patients had to have protocol kidney biopsy at the time of implantation and 12
7
8 months after transplantation. Exclusion criteria have been: dual kidney transplantation,
9
10 kidney-liver transplantation, use of antithymocyte immunoglobulin, BK nephropathy and
11
12 recurrence of glomerulonephritis after transplantation.
13
14

15
16
17
18
19
20
21
22
23 *Immunosuppression:*

24
25 Induction immunosuppression consisted of an anti-IL2 antibody (daclizumab or
26
27 basiliximab), calcineurin inhibitor (tacrolimus or cyclosporine), MMF and
28
29 methylprednisolone. Maintenance immunosuppression consisted of a calcineurin
30
31 inhibitor (tacrolimus or cyclosporine), MMF ± steroids. Target cyclosporine trough
32
33 concentrations were 250-350 during first month posttransplant, 200-300 during second to
34
35 6th month and 100-150 µg/L thereafter. Target tacrolimus trough levels were 10-12
36
37 during first month, 8-10 during second to 6th month and 5-8 µg/L thereafter.

38
39 Mycophenolic acid target trough concentration was aimed to be higher than 7.2 µmol/L
40
41 with tacrolimus and higher than 5 µmol/L with cyclosporine use.
42

43
44 Daclizumab was administered at day 0: 2mg/kg i.v. before opening of vascular
45
46 anastomosis and at day 14: 2mg/kg i.v.. Basiliximab was administered at day 0: 20 mg
47
48 i.v. before opening of vascular anastomosis and at day 4: 20 mg i.v..
49

50
51 Steroids have been dosed as follows: day 0: intraoperatively 500 mg of
52
53 methylprednisolone, day 1: 250 mg, day 2: 125mg, day 3: 80 mg and day 4: 40 mg. In
54
55 patients with early steroid withdrawal steroids have been withdrawn at day 5 after
56
57 transplantation. In patients maintained on steroids, nadir dose of prednisone was 5 mg/d,
58
59
60

1
2
3
4
5 achieved by 6 months. The criteria for early elimination of steroids were low
6
7 immunological risk of the recipient (absence of, or low degree of HLA sensitization,
8
9 i.e. PRA <10%) and good immediate renal function, as well as absence of an episode of
10
11 acute rejection within 5 days after the transplantation. Steroids have been reintroduced in
12
13 patients who suffered acute rejection episode.

14
15 As prophylaxis for viral (HSV, CMV), fungal (Candida spp.) urinary and P. jiroveci
16
17 infections, low-dose fluconazole (for one year), valganciclovir (universally for three
18
19 months) and sulfomethoxazol and trimethoprim (for one year) was used.
20
21
22
23
24
25
26
27
28

29 *Renal allograft biopsies:*

30
31 Protocol kidney biopsies were done at implantation, 1, 3, 6 and 12 months after
32
33 transplantation. For cause biopsies were done in case of unexplained deterioration of
34
35 renal function, or once weekly in patients with DGF. All rejection episodes were
36
37 histologically confirmed. Histopathological analysis was performed by either of two
38
39 pathologists who were blinded for immunosuppression. Acute rejections and chronic
40
41 allograft scores have been analyzed using Banff 97 classification and its updates.[14, 15]
42
43 All protocol and indication biopsies were analyzed by light microscopy, by
44
45 immunofluorescence for C4d, and if indicated by immunohistochemistry for BK virus.
46
47 Biopsies at 1 year post transplant have been also analyzed by electron microscopy for
48
49 signs of chronic antibody-mediated rejection (transplant glomerulopathy, peritubular
50
51 capillary basement membrane multilayering).[16]
52
53
54
55

56 *Clinical outcome parameters:*

57
58
59
60

1
2
3
4 Progression of chronic allograft scores during 1 year posttransplant was calculated by
5 subtracting implantation chronic scores from chronic allograft scores 12 months
6
7 posttransplant: interstitial fibrosis (Δci), tubular atrophy (Δct), glomerulosclerosis (Δcg),
8
9 mesangial matrix increase (Δmm), vasculopathy (Δcv) and arteriolar hyalinosis (Δah).
10
11 Estimated creatinine clearance (eCr_{cl}) at 3, 6 and 12 months posttransplant was calculated
12
13 using Cockcroft-Gault formula. Acute rejections with Banff grade IA and IB were treated
14
15 with three 500 mg methylprednisolone pulses. In case of acute rejection grade IIA or
16
17 greater, patients have been treated with antithymocyte globulin. Antibody-mediated
18
19 rejections were treated with steroid pulse and plasmapheresis.
20
21
22 Average dose of MMF during 1 year posttransplant was calculated from MMF dose at
23
24 month 1, 3, 6 and 12.
25
26
27 Adverse effects analysed were clinically significant leucopenia, defined as white blood
28
29 cell count less than 3000/ml, time to first symptomatic infection and number of
30
31 symptomatic infection episodes per patient during first post transplant year.
32
33
34

35 *Statistical analysis:*

36
37 Numerical data are presented as mean \pm SD or median with range in case of not normal
38
39 distribution. Normality of distribution has been tested with Kolmogorov-Smirnov test.
40
41 Correlation between two continuous variables has been tested using Spearman
42
43 nonparametric correlation. Difference between two groups in continuous variables has
44
45 been tested with student t-test or with Mann-Whitney test in non-normally distributed
46
47 variables. The significance of the progression in chronic scores was analyzed using
48
49 Wilcoxon Matched Pairs test. Univariate and multiple linear regression analysis were
50
51 performed to determine predictive factors for progression of chronic allograft scores and
52
53 kidney function at 12 months after transplantation. All variables that were associated with
54
55 respective outcome in bivariate analysis (at $p=0.1$) were included in multivariate
56
57
58
59
60

1
2
3
4
5 analysis. Because of colinearity between ci and ct score, only one score was included in
6
7 each multivariate analysis. Statistical significance was considered at $p < 0.05$. All
8
9 statistical analyses were performed using Statistica 10 (StatSoft, Tulsa, OK, USA).

10 11 12 RESULTS:

13 14 15 *Patient and transplant characteristics:*

16
17 Patient characteristics are shown in Table 1. Recipients were a mean of 44.67 ± 12.03
18
19 years old at the time of transplantation, 68 percent of them were male and all were
20
21 Caucasians. 33 percent of recipients had DGF after transplantation. Donors were a mean
22
23 of 43.89 ± 15.55 years old and 54 percent of them were male. Number of living donor
24
25 transplantations was 24 (30 percent). Average daily MMF dose during 1 year
26
27 posttransplant was 2244 ± 585 mg (1062 – 4000) (Table 2). As expected, there was no
28
29 correlation of MMF dose with MMF trough concentration ($R = -0.13$; $p = 0.28$). Also, there
30
31 was no correlation between MMF dose with tacrolimus concentration ($R = -0.04$; $p = 0.79$).
32
33 Early steroid withdrawal was done in 46 percent of patients after transplantation.
34
35 Incidence of subclinical and clinical acute rejections greater than borderline was 30
36
37 percent in first year. There was no correlation between average MMF dose and incidence
38
39 of acute rejection ($p = 0.68$).
40
41
42
43
44
45
46
47
48
49

50 51 *Factors associating with eCr_{cl}:*

52
53 Kidney function increased during 1st year post transplant. eCr_{cl} at month 3 was $56.98 \pm$
54
55 15.78 ml/min, at 6 month 58.94 ± 16.94 ml/min and at 12 month 61.47 ± 16.75 ml/min
56
57 ($p < 0.001$; 12 months vs. 3 months) (Figure 1.) eCr_{cl} at 1 year post transplant was greater
58
59
60

1
2
3
4 in SPKT recipients (71.38 ± 13.45 ml/min vs. 57.88 ± 16.47 ml/min; $p=0.001$) and in
5 patients who did not have DGF (64.08 ± 15.87 ml/min vs. 56.15 ± 17.55 ml/min; $p=0.05$).
6
7 Donor age ($R=-0.46$; $p<0.001$) and recipient age ($R=-0.46$; $p<0.001$) negatively
8 correlated with eCr_{cl} at 1 year post transplant, while there was no correlation of renal
9 function with donor and recipient gender, type of donation (deceased vs. living), HLA
10 MM, average CNI concentration, steroid-free regimen of immunosuppression, or history
11 of acute rejection (Table 3). In univariate analysis allograft function at 12 month post Tx
12 was also negatively correlated with ci ($R=-0.34$; $p=0.002$) and ct ($R=-0.35$; $p=0.002$) at
13 12 month (Figure 2A, Figure 2B). Although MMF dose was positively correlated with
14 renal function with borderline significance in univariate analysis, in multivariate analysis
15 there was a significant positive association between greater average MMF dose and better
16 eCr_{cl} at 12 month post transplant ($b=0.21 \pm 0.1$; $p=0.04$) (Table 4).
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 *Factors affecting IF/TA:*

32
33 The average ci score increased from 0.16 ± 0.44 to 0.94 ± 0.86 between implantation and
34 month 12 ($p<0.001$). Average progression of this and other chronic scores during 1 year
35 post transplant is shown in Table 5. In univariate analysis Δci ($R=-0.37$; $p=0.001$) and Δct
36 ($R=-0.38$; $p=0.001$) significantly negatively correlated with average MMF dose (Figure
37 3A and 3B, Table 6). There was lower progression of ci score in patients on steroid-free
38 immunosuppression (0.47 ± 0.7 vs. 1.09 ± 0.87 ; $p=0.002$) and in those who did not have
39 DGF (0.62 ± 0.74 vs. 1.19 ± 0.98 ; $p=0.02$). Acute cellular rejection, recipient and donor
40 gender, recipient and donor age, HLA MM, deceased vs. living donor, as well as average
41 concentration of tacrolimus had no significant effect on progression of chronic allograft
42 scores. Higher average MMF dose was associated with lower progression of ci and ct
43 score regardless CNI type (data not shown). Factors that remained significantly
44 associated with progression of ci score in multivariate analysis were ci_0 score, donor age,
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 average MMF dose, DGF and steroid-free immunosuppression (Table 7.). In multivariate
5
6 analysis only ct0 score, average MMF dose and DGF remained independently associated
7
8 with 12-month progression of ct score (Table 7.). Selected AE are shown in Table 8.

9
10 There was no difference in AE (leucopenia and infections) with respect to average
11
12 median MMF dose.
13

14 15 Discussion: 16

17
18
19
20
21 The most important novel finding in our study is that greater average MMF exposure was
22
23 strongly negatively correlated with IF/TA progression during first year after kidney
24
25 transplantation. Patients on higher average dose of MMF during 1 year post
26
27 transplantation had significantly lower progression of ci and ct scores. To our knowledge
28
29 this is first study demonstrating that there is a dose-dependent protective effect of MMF
30
31 on graft IF/TA. Lower progression of IF/TA could not be explained with lower
32
33 concentration of CNI, because there was not correlation between tacrolimus
34
35 concentration with IF/TA. Similarly, there was no correlation between average MMF
36
37 dose and tacrolimus ($R=-0.04$; $p=0.79$) or cyclosporine concentration ($R=-0.07$, $p=0.79$).
38
39 In addition, higher average MMF dose was not associated with decreased incidence of
40
41 biopsy proven acute rejection, which suggests that antifibrotic properties of higher MMF
42
43 dose was at least partly independent of its immunosuppressive effects. Higher MMF dose
44
45 had only moderate effect on 1-year renal function, which is consistent with previous
46
47 reports showing that transplanted kidneys undergo pathohistology changes without
48
49 significant early change in kidney function.[17]

50
51 In the present retrospective study we have confirmed that IF/TA progression occurs in
52
53 first year after kidney transplantation. Several studies have shown that progression of
54
55 IF/TA is correlated with type of immunosuppression.[18] In most transplant centers in
56
57
58
59
60

1
2
3
4 the United States and Europe immunosuppression consists of induction with an anti-IL2R
5 antibody or antithymocyte immunoglobulin and maintenance with a calcineurin inhibitor,
6 MMF and steroids.[19] Studies have reported significant improvement in kidney function
7 in patients on MMF with lower exposition to CNIs, esp. tacrolimus.[20] Recently, in the
8 paper of Kamar *et al.* it has been reported that maintenance kidney transplant patients
9 converted to a higher dose of the mycophenolate sodium (1440 mg daily) with lower
10 tacrolimus concentration had borderline higher eCr_{cl} on month 6 vs. those treated with
11 lower dose of mycophenolate sodium, with usual tacrolimus concentration (eCr_{cl} 49.1 ±
12 11.1 vs. 44.7 ± 11.5 ml/min; p=0.07).[21] Although there was only borderline
13 significance, increased mycophenolate dosing with lower tacrolimus concentration was
14 safe with potential benefit on kidney function.

15
16
17
18
19
20
21
22
23
24
25
26
27 Our study also corroborates recently published findings of a *post hoc* joint analysis of the
28 Symphony, FDCC and OptiCept trials, where a a lower tacrolimus level and a higher
29 MMF dose were associated with significantly better kidney function at 1 year post
30 transplant.[22] Shortcoming of these studies[17,18] is lack of protocol biopsies. The
31 optimal MMF dosing in patients maintained on contemporary low-dose CNI is still
32 undetermined. However, some results of early MMF registration trials suggest that higher
33 MMF exposure might be beneficial; having in mind that there was no antibody induction
34 in these studies and that CNI was standard dose cyclosporine. Thus, in the Tri-continental
35 study, group treated with 3 g MMF compared with 2 g of MMF showed lower incidence
36 of biopsy proven acute rejection episodes (15.9% vs. 19.7%) within 6 month period
37 selected for the primary efficacy analysis. Similarly, serum creatinine level at 1 year was
38 1.42 ± 0.07 mg/dL in the MMF 3 g group vs. 1.64 ± 0.07 mg/dL in MMF 2 g group.[12]
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
In the European mycophenolate mofetil study same trends regarding higher MMF dose
were observed.[11] As mentioned before, in these studies there was no antibody
induction that could have allowed lower dose of cyclosporin with higher dose of MMF

1
2
3
4 and there were no protocol biopsies. In a more recent MYSS trial, there was no difference
5
6 in acute rejection rate and renal function between MMF and azathioprine in a
7
8 cyclosporine-based protocol.[19] However in that study only one MMF dose was
9
10 compared to azathioprine[23] and again there were no protocol biopsies.

11
12 Unfortunately adequate prospective MMF dose comparison studies in tacrolimus-based
13
14 protocols with antibody induction are missing. In the Symphony study it was reported
15
16 that patients on tacrolimus-MMF-prednisone maintenance immunosuppression after kidney
17
18 transplantation had better kidney function and graft survival with lower number of acute
19
20 rejection episodes. Patients in that group had highest MMF exposure.[24] Protocols with
21
22 even higher MMF exposure might allow additional CNI sparing, that would decrease side
23
24 effect of CNI (hypertension, diabetes, hyperlipidemia, neurotoxicity).[25]
25
26

27
28 Clinical relevance of IF/TA without other concomitant pathology (i.e. recurrent disease
29
30 and chronic antibody-mediated rejection) for prediction of graft deterioration and loss is
31
32 controversial. In El-Zoghby et al. study there was attempt to identify specific causes of
33
34 late kidney allograft failure. The authors found that transplant glomerulopathy was
35
36 responsible for 37 percent loss of functioning grafts, while graft loss due to IF/TA was
37
38 present in 31 percent of cases (with higher frequency in deceased-donor transplants).[26]

39
40 At first glance, these results seem at odd with ours, where there were no signs of chronic
41
42 antibody-mediated rejection. An explanation for this discrepancy in the results of the two
43
44 studies is not completely clear, but the former study included high number of living
45
46 transplants (72.5 percent) with glomerulonephritis as primary disease and with follow-up
47
48 up to 10 years. Transplant glomerulopathy is more frequently seen late posttransplant,
49
50 generally with low incidence. Nevertheless, ours and El-Zoghby study, both
51
52 demonstrated that IF/TA even in absence of other pathology is associated with adverse
53
54 graft outcome. Another important study, the DeKaf study, tried to use various
55
56 histopathologic clusters to differentiate subgroups within diagnosis of IF/TA. They found
57
58
59
60

1
2
3
4 that cluster with more severe fibrosis plus inflammation and arterial lesions had the worst
5 prognosis.[27] Although incidence of acute rejection in our study did not vary with MMF
6 exposure, increased MMF exposure might suppress mild graft inflammation, below the
7 threshold for diagnosing acute rejection. This is subject of our ongoing investigation and
8 will be reported separately. An interesting finding of the present study was that early
9 steroid withdrawal was not associated with worse IF/TA. At first glance this is at odd
10 with the Astellas trial.[23] However, according to our protocol, patients with DGF were
11 not included in early steroid withdrawal and Astellas trial, which did not have protocol
12 biopsies, reported increased IF/TA in early steroid withdrawal group based on indication
13 biopsies performed early posttransplant, thus more likely reflecting donor-derived
14 histology changes, rather than effect of steroid withdrawal.[28]

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
In our study there was only borderline significance of positive association of 1-year eCrCl
with MMF in univariate analysis. This result is not very surprising since decreased renal
function is not a very sensitive marker of incipient IF/TA.

Mechanisms by which an average higher exposure to MMF was associated with slower
progression of IF/TA may be both immune and nonimmune. Because there was no
difference in incidence of acute rejection with respect to increased MMF exposure in our
study, we believe that there may be a significant contribution of nonimmune mechanisms
in retardation of IF/TA in patients with higher MMF. In line with this, in many
experimental models it has been shown that MMF has antiproliferative and antifibrotic
effect.[29-31] In the study of Jiang at al. using rat renal ischemia reperfusion injury, a
time- and dose-dependent correlation of higher MMF dose with better renal function and
lower interstitial fibrosis was demonstrated. Suggested potential mechanism was lower
expression of TGF- β 1 and MCP-1 with lower macrophage infiltration.[32] In recent
clinical trials MMF was shown as a safe drug that could be a good candidate for
treatment of interstitial lung disease in systemic sclerosis.[33] Experimental model of

1
2
3
4 encapsulated peritoneal sclerosis in rats proved beneficial effect of MMF as an inhibitor
5 of neovascularisation.[34] Also, MMF monotherapy was associated with a positive effect
6
7 on hepatic fibrosis progression in HCV liver transplant recipients.[35]
8
9

10 Our study has several shortcomings, such as its retrospective aspect and relatively short
11 study period. Although study period was limited to 12 months post transplantation, a
12 clear correlation of slower progression of IF/TA with higher average MMF dose
13 underlines potential benefit of these findings. As mentioned before, in current study we
14 did not analyze inflammation outside Banff acute rejection threshold in kidney biopsies
15 with respect to MMF dose. As inflammation in areas of IF/TA is an important predictor
16 of renal function and graft loss, this is subject of an ongoing work.
17
18
19
20
21
22
23
24

25 In summary, higher MMF dose after kidney transplantation might slower progression of
26 IF/TA, which might lead to better long-term survival of transplanted kidney. Our study
27 serves as a platform for a prospective, randomized, long-term trial with different MMF
28 doses to evaluate benefit of higher MMF dose in renal transplant recipients.
29
30
31
32

33 (NCT018600183).
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgments:

This manuscript has not been published elsewhere, beside as a part of 2011 ASN Annual meeting abstract.

Contributorship Statement

Karlo Mihovilović – participated in research design, collecting data, analyzing data and wrote the paper, karlomihovilovic@gmail.com

Bojana Maksimović - participated in collecting and analyzing data, bmaximovic@gmail.com

Branislav Kocman - participated in collecting data, branislav.kocman@gmail.com

Denis Guštin - participated in collecting data, denis.gustin@zg.t-com.hr

Željko Vidas – participated in collecting data, zeljko.vidas1@zg.t-com.hr

Stela Bulimbašić - participated in collecting and analyzing data, stela.bulimbasic@gmail.com

Danica Galešić Ljubanović – participated in collecting and analyzing data,
danica.ljubanovic@zg.htnet.hr

Mirjana Sabljar Matovinović – participated in collecting data, mirjana.sabljar-
matovinovic@zg.t-com.hr

Mladen Knotek- proposed research design, analyzed data and participated in writing the paper,
mladen.knotek1@zg.t-com.hr

Support and Financial Disclosure Declaration:

Source of support: Grant by the Ministry of Science, Technology and Sports of the Republic of Croatia to Dr. Mladen Knotek.

Disclosures:

The authors of this manuscript have no conflicts of interest to disclose.

Data Sharing Statement: No additional data available.

Abbreviations:

IF/TA - interstitial fibrosis and tubular atrophy

MMF - mycophenolate mofetil

BK - polyoma virus BK

CNI - calcineurin inhibitors

DGF - delayed graft function

eCrCl - estimated creatine clearance

SPKT - simultaneous pancreas kidney transplantation

HLA MM – human leukocyte antigen mismatch

AE - adverse events

Figure Legends

Figure 1: Estimated creatinine clearance during first year posttransplant

Figure 2A: Correlation between average MMF dose and progression of ci score

Figure 2B: Correlation between average MMF dose and progression of ct score

Figure 3A: Estimated creatinine clearance by ci score

Figure 3B: Estimated creatinine clearance by ct score

Reference List

- 1 Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. *N Engl J Med* 2002; 346:580-590.
- 2 Kuypers DR, Chapman JR, O'Connell PJ et al. Predictors of renal transplant histology at three months. *Transplantation* 1999; 67:1222-1230.
- 3 Matas AJ, Gillingham KJ, Payne WD et al. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). *Transplantation* 1994;57:857-859.
- 4 Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. *N Engl J Med* 2003; 349:2326-2333.
- 5 Birnbaum LM, Lipman M, Paraskevas S et al. Management of chronic allograft nephropathy: a systematic review. *Clin J Am Soc Nephrol* 2009; 4:860-865.
- 6 Frimat L, Cassuto-Viguiet E, Charpentier B et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. *Am J Transplant* 2006; 6:2725-2734.
- 7 Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. *N Engl J Med* 2007; 357:2562-2575.
- 8 Azuma H, Binder J, Heemann U et al. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. *Transplantation* 1995; 59:460-466.
- 9 Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. *Transplantation* 2000; 69:2405-2409.
- 10 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. *Transplantation* 1996; 61,722-729.
- 11 European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. *Lancet* 1995; 345, 1321-1325.
- 12 Djamali A, Vidyasagar A, Yagci G et al. Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway. *Transplantation* 2010;90:387-393.

- 1
2
3
4 13 Dell'Oglio MP, Zaza G, Rossini M et al. The anti-fibrotic effect of mycophenolic
5 acid-induced neutral endopeptidase. *J Am Soc Nephrol* 2010; 21:2157-2168.
6
7 14 Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft
8 pathology: updates and future directions. *Am J Transplant* 2008; 8:753-760.
9
10 15 Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of
11 renal allograft pathology. *Kidney Int* 1999; 55:713-723.
12
13 16 Roufosse CA, Shore I, Moss J et al. Peritubular capillary basement membrane
14 multilayering on electron microscopy: a useful marker of early chronic antibody-
15 mediated damage. *Transplantation* 2012; 94:269-274.
16
17 17 Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft
18 nephropathy. *N Engl J Med* 2003; 349:2326-2333.
19
20 18 Gelens MA, Steegh FM, van Hooff JP et al. Immunosuppressive Regimen and
21 Interstitial Fibrosis and Tubules Atrophy at 12 Months Postrenal Transplant. *Clin*
22 *J Am Soc Nephrol* 2012; 5:1010-1017.
23
24 19 Available at:
25 http://srr.transplant.hrsa.gov/annual_reports/2011/pdf/01_kidney_12.pdf. 2013.
26
27
28
29
30
31 20 Ekberg H, van GT, Kaplan B et al. Relationship of tacrolimus exposure and
32 mycophenolate mofetil dose with renal function after renal transplantation.
33 *Transplantation* 2011; 92:82-87.
34
35 21 Kamar N, Rostaing L, Cassuto E et al. A multicenter, randomized trial of
36 increased mycophenolic acid dose using enteric-coated mycophenolate sodium
37 with reduced tacrolimus exposure in maintenance kidney transplant recipients.
38 *Clin Nephrol* 2012 ;77:126-136.
39
40 22 Ekberg H, van GT, Kaplan B et al. Relationship of tacrolimus exposure and
41 mycophenolate mofetil dose with renal function after renal transplantation.
42 *Transplantation* 2011; 92:82-87.
43
44 23 Remuzzi G, Lesti M, Gotti E et al. Mycophenolate mofetil versus azathioprine for
45 prevention of acute rejection in renal transplantation (MYSS): a randomised trial.
46 *Lancet* 2004; 364:503-512.
47
48 24 Lloberas N, Torras J, Cruzado JM et al. Influence of MRP2 on MPA
49 pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic
50 Substudy within the Symphony Study. *Nephrol Dial Transplant* 2011; 26:3784-
51 3793.
52
53 25 Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes
54 after renal transplantation. *N Engl J Med* 2002; 346:580-590.
55
56
57
58
59
60

- 1
2
3
4 26 El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney
5 allograft loss. *Am J Transplant* 2009;9:527-535.
6
7 27 Matas AJ, Leduc R, Rush D et al. Histopathologic clusters differentiate subgroups
8 within the nonspecific diagnoses of CAN or CR: preliminary data from the
9 DeKAF study. *Am J Transplant* 2010; 10:315-323.
10
11 28 Woodle ES, First MR, Pirsch J et al. A prospective, randomized, double-blind,
12 placebo-controlled multicenter trial comparing early (7 day) corticosteroid
13 cessation versus long-term, low-dose corticosteroid therapy. *Ann Surg*; 248: 564-
14 577.
15
16
17 29 Luo L, Sun Z, Wu W et al. Mycophenolate mofetil and FK506 have different
18 effects on kidney allograft fibrosis in rats that underwent chronic allograft
19 nephropathy. *BMC Nephrol* 2012;13:53.
20
21
22 30 Jiang S, Tang Q, Rong R et al. Mycophenolate mofetil inhibits macrophage
23 infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. *Eur J*
24 *Pharmacol* 2012; 688:56-61.
25
26
27 31 Dell'Oglio MP, Zaza G, Rossini M et al. The anti-fibrotic effect of mycophenolic
28 acid-induced neutral endopeptidase. *J Am Soc Nephrol* 2010; 21:2157-2168.
29
30 32 Jiang S, Tang Q, Rong R et al. Mycophenolate mofetil inhibits macrophage
31 infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. *Eur J*
32 *Pharmacol* 2012; 688:56-61.
33
34
35 33 Tzouveleakis A, Galanopoulos N, Bouros E, et al. Effect and safety of
36 mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung
37 disease: a meta-analysis. *Pulm Med* 2012; 1-7.
38
39 34 Hur E, Bozkurt D, Timur O, et al. The effects of mycophenolate mofetil on
40 encapsulated peritoneal sclerosis model in rats. *Clin Nephrol* 2012; 77:1-7.
41
42
43 35 Manzia TM, Angelico R, Toti L et al. Long-term, maintenance MMF
44 monotherapy improves the fibrosis progression in liver transplant recipients with
45 recurrent hepatitis C. *Transpl Int* 2011; 24:461-468.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

20

Table 1. Baseline characteristics

RECIPIENT CHARACTERISTICS	AGE (years)	44.67 ± 12.03
	GENDER (f/m)	25/54
	PRIMARY RENAL DISEASE (diabetes mellitus, polycystic kidney disease, glomerulonephritis, pyelonephritis/interstitial nephritis, other/unknown)	24/8/19/6/22
DONOR CHARACTERISTICS	DONOR SOURCE (deceased/living)	55/24
	AGE (years)	43.89 ± 15.55
	GENDER (f/m)	36/43
TRANSPLANTATION CHARACTERISTICS	TRANSPLANTED ORGAN (KIDNEY/SPKT)	58/21
	INITIAL IMMUNOSUPPRESSION (anti-IL2,TAC,MMF/anti-IL2, CyA,MMF)	53/26
	DELAYED GRAFT FUNCTION (no/yes)	53/26
	STEROID FREE (yes/no)	36/43
	HLA MM	3.33 ± 1.51

Table 2. eCr_{cl}, MMF dose and CNI concentration during first year post transplant

Month posttransplant	1	3	6	12
eCr _{cl} (ml/min)		56.98 ± 15.79	58.94 ± 16.94	61.47 ± 16.75
MMF dose (mg)	2500 (750 – 4000) 2427 ± 643.17	2000 (750 – 4000) 2167.72 ± 733.49	2000 (1000-4000) 2188.29 ± 716.91	2000 (1000-4000) 2193.04 ± 642.95
Tacrolimus conc. (µg/L) (n=53)	10.79 ± 4.16	9.69 ± 3.00	9.03 ± 5.52	7.83 ± 2.45
Cyclosporin conc. (µg/L) (n=26)	335.07 (274 – 413)	231.05 (181-265)	206 (170 – 257)	131 (125 – 171)

Table 3. Association of variables with eCr_{cl} on 1 year

	Estimated creatinine clearance (ml/min)	p value
Kidney vs. SPKT	57.88 ± 15.47 vs. 71.38 ± 13.45	0.001
DGF (yes vs. no)	56.15 ± 17.55 vs. 64.08 ± 15.87	0.05
Recipient gender (m vs. f)	59.83 ± 16.02 vs. 65 ± 18.07	0.2
Donor gender (m vs. f)	63.87 ± 16.71 vs. 58.60 ± 16.58	0.17
Donor source (D vs. L)	62.36 ± 17.85 vs. 59.43 ± 14.05	0.47
Steroid-free (yes vs. no)	63.94 ± 17.73 vs. 59.39 ± 15.81	0.23
Acute rejection (yes vs. no)	61.64 ± 16.59 vs. 61.39 ± 16.97	0.95
	R	p value
Recipient age	-0.45	<0.0 01
Donor age	-0.46	<0.0 01
HLA MM	0.07	0.52
Average tacrolimus concentration	-0.02	0.9
Average MMF dose	0.18	0.1
ci at 1 year post Tx	-0.34	0.002
ct at 1 year post Tx	-0.35	0.002
cv at 1 year post Tx	-0.20	0.07

Table 4. Multiple regression analysis of factors associated with kidney function

	Beta (β)	St.Err β	p value
Tx (kidney)	-0.17	0.13	0.19
DGF (no)	0.04	0.1	0.71
Recipient age	-0.41	0.1	<0.001
Donor age	-0.1	0.14	0.45
ci at 12 months	-0.18	0.11	0.09
Average MMF dose	0.21	0.1	0.04

Table 5. One-year progression of chronic allograft scores

Banff score	N	At transplantation	N	12 month	p
Interstitial fibrosis (ci)	79	0.16 ± 0.44	79	0.94 ± 0.85	<0.001
Tubular atrophy (ct)	79	0.24 ± 0.46	79	1.05 ± 0.77	<0.001
Chronic glomerulopathy (cg)	79	0	79	0	
Mesangial matrix (mm)	79	0.01 ± 0.11	79	0.09 ± 0.36	0.09
Fibrintimal thickening (cv)	76	0.37 ± 0.83	78	0.29 ± 0.70	0.47
Arteriolar hyalinosis (ah)	78	0.68 ± 1,04	79	0.79 ± 1.04	0.26

Table 6. Correlation of factors associated with progression of ci and ct scores

	Δ ci	Δ ct		
	mean \pm SD	p	mean \pm SD	p
Kidney vs. SPKT	0.86 \pm 0.91 vs. 0.67 \pm 0.73	0.51	0.85 \pm 0.87 vs. 0.86 \pm 0.65	0.74
DGF (yes vs. no)	1.19 \pm 0.98 vs. 0.62 \pm 0.74	0.02	1.15 \pm 0.92 vs. 0.69 \pm 0.72	0.05
Recipient gender (m vs. f)	0.83 \pm 0.88 vs. 0.76 \pm 0.83	0.78	0.91 \pm 0.83 vs. 0.72 \pm 0.79	0.35
Donor gender (m vs. f)	0.91 \pm 0.95 vs. 0.69 \pm 0.75	0.43	0.88 \pm 0.93 vs. 0.81 \pm 0.67	0.96
Donor source (D vs. L)	0.84 \pm 0.88 vs. 0.75 \pm 0.85	0.73	0.87 \pm 0.82 vs. 0.79 \pm 0.83	0.71
Steroid free (no vs. yes)	1.09 \pm 0.87 vs. 0.47 \pm 0.74	0.002	1.07 \pm 0.83 vs. 0.58 \pm 0.73	0.01
Acute rejection (yes vs. no)	0.8 \pm 0.89 vs. 0.83 \pm 0.82	0.78	0.93 \pm 0.84 vs. 0.67 \pm 0.76	0.23
	R	p	R	p
Recipient age	-0.11	0.33	-0.11	0.32
Donor age	0.17	0.13	0.04	0.73
HLA MM	-0.09	0.43	-0.002	0.99
Average tacrolimus conc.	-0.009	0.95	0.003	0.98
Average MMF dose	-0.37	<0.001	-0.38	<0.001
ci at implantation	-0.32	0.003		
ct at implantation			-0.45	<0.001

26

Table 7. Multivariate general regression analysis for factors related to progression of ci and ct score

	Beta (β)	Std. Err. β	p
ci0	-0.43	0.09	<0.001
DGF (no)	-0.22	0.11	<0.05
Average MMF dose	-0.20	0.09	<0.05
Donor age	0.32	0.09	<0.05
Steroid free (yes)	-0.25	0.11	0.02
Δ ct			
	Beta (β)	Std. Err. β	p
ct0	-0.44	0.09	<0.001
Average MMF dose	-0.29	0.1	<0.05
DGF (no)	-0.29	0.1	<0.05
Steroid free (yes)	-0.09	0.11	0.39

Table 8. Adverse events with respect to 1 year average median MMF dose.

	MMF dose < median	MMF dose > median	p
Average number of infection episodes per patient	1.16 ± 0.97	1.23 ± 1.22	0.88
Mean time to first infection (days)	157±138	175±143	0.76
Proportion of patients with leucopenia	6 /31	7 /48	0.58

1
2
3 **Effect of Mycophenolate Mofetil on Progression of Interstitial Fibrosis and Tubular**
4
5 **Atrophy after Kidney Transplantation - A Retrospective Study**
6
7
8
9

10 Karlo Mihovilović¹, Bojana Maksimović¹, Branislav Kocman², Denis Guštin³, Željko Vidas⁴,
11
12 Stela Bulimbašić⁶, Danica Galešić Ljubanović^{5,6}, Mirjana Sabljar Matovinović¹, Mladen
13
14
15 Knotek^{1,5}
16
17
18
19

20 Clinical Hospital Merkur: ¹Department of Medicine, Renal Division, ²Department of Surgery,
21
22 ³Department of Anaesthesiology, ⁴Department of Urology; ⁵University of Zagreb School of
23
24
25 Medicine, Zagreb, Croatia, Clinical Hospital Dubrava: ⁶Department of Pathology
26
27
28
29

30 **Keywords:** interstitial fibrosis, tubular atrophy, kidney function, myophenolate mofetil
31

32 Word count: Abstract-238
33

34 Manuscript- 3049
35

36 **Number of tables: 8**
37

38 **Number of figures: 3**
39
40

41 **Corresponding author:** Dr. Mladen Knotek
42

43 Department of Medicine, Renal Division
44

45 Clinical Hospital Merkur
46

47 Zajceva 19
48

49 10000 Zagreb
50

51 Croatia
52

53 e-mail: mladen.knotek1@zg.t-com.hr (this e-mail address can be published)
54

55 phone: +38512431123, fax: +38512431123
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT:

Objectives - Chronic transplant dysfunction after kidney transplantation is major reason of kidney graft loss and is caused by immunological and non-immunological factors.

There is evidence that mycophenolate mofetil (MMF) may exert a positive effect on renal damage in addition to immunosuppression, by its direct antifibrotic properties. The aim of our study was to retrospectively investigate role of MMF dose on progression of chronic allograft dysfunction and IF/TA.

Setting - Retrospective, cohort study.

Participants - Kidney transplant patients in tertiary care institution. This is a retrospective cohort study that included 79 patients with kidney and kidney-pancreas transplantation. Immunosuppression consisted of anti-IL2 antibody induction, MMF, a calcineurin inhibitor \pm steroids.

Primary outcome measures - An association of average MMF dose over 1 year post transplant with progression of interstitial fibrosis (Δ ci), tubular atrophy (Δ ct) and estimated creatinine clearance (eCrcl) at 1 year post transplant was evaluated using univariate and multivariate analyses.

Results - Higher average MMF dose was significantly independently associated with better eCrcl at 1 year post transplant ($b=0.21 \pm 0.1$, $p=0.04$). In multiple regression analysis lower Δ ci ($b=-0.2 \pm 0.09$, $p=0.05$) and Δ ct ($b=-0.29 \pm 0.1$, $p=0.02$) were independently associated with greater average MMF dose. There was no correlation between average MMF dose and incidence of acute rejection ($p=0.68$).

1
2
3 **Conclusions** - Higher average MMF dose over 1 year is associated with better renal
4
5 function and slower progression of IF/TA, at least partly independent of its
6
7 immunosuppressive effects.
8
9

10 11 12 **Strengths and limitations of this study**

13
14 Important novel finding in our study is that greater average MMF exposure was strongly
15
16 negatively correlated with IF/TA progression during first year after kidney
17
18 transplantation. Patients on higher average dose of MMF (up to 4 g daily) during 1 year
19
20 post transplantation had significantly lower progression of graft interstitial fibrosis and
21
22 tubular atrophy. This is important finding, because of predictive value of graft IF/TA and
23
24 should translate into better long-term graft survival. Our study has several shortcomings,
25
26 such as its retrospective aspect and relatively short study period. As it was not aim of the
27
28 study, we did not report side effects associated with different dosage of MMF.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION:

Kidney transplantation significantly improves patient survival and quality of life comparing to dialysis. While significant improvements have been made in the treatment of acute rejection and short survival of transplanted kidney, there has not been major improvement in the long-term survival of transplanted kidney.[1] Chronic transplant dysfunction after kidney transplantation is major cause of kidney graft loss and is evoked by immunological and non-immunological factors.[2, 3] Histology changes that determine chronic transplant dysfunction are interstitial fibrosis and tubular atrophy (IF/TA), arteriosclerosis, arteriolar hyalinosis, glomerulopathy and mesangial matrix expansion.[4] IF/TA is the major pathohistology finding that can be verified on graft biopsies after kidney transplantation and is a predictor of long-term allograft function.[4] Clinical factors that affect progression of IF/TA are: recipient age, HLA mismatch, episodes of severe acute rejection, chronic rejection (esp. antibody-mediated), use of calcineurin inhibitors and BK nephropathy. Avoidance of CNI toxicity is considered as an important step to slow progression of IF/TA.[4-7] Mycophenolate mofetil (MMF) may help lowering CNI toxicity, by allowing lower CNI exposure.[7] MMF reduces the risk of acute allograft rejection, without nephrotoxic side effects and is ideal candidate for long-term calcineurin drug reduction treatment strategies.[7] Retrospective studies of renal recipients who were treated with mycophenolate mofetil comparing azathioprin showed that MMF treated patients had significantly less chronic allograft dysfunction.[8, 9] Besides being associated with lower acute rejection rates as compared to azathioprin,[10, 11] evidence from animal and human studies suggests that

MMF may also exert a direct antifibrotic properties due to its antiproliferative action on nonimmune cells, including renal tubular cells and vascular smooth muscle cells.[12, 13]

The aim of our study was to investigate role of mycophenolate mofetil dose on progression of IF/TA in kidney transplant recipients.

PATIENTS AND METHODS:

Patients:

This is a retrospective study conducted at Clinical Hospital “Mercur”. This study represents a part of the posttransplant immune monitoring at the Mercur hospital, approved by the Hospital Ethics Committee. Patients gave there informed written consent for anonymized transplant data collection for research purposes. The study included 79 patients with kidney and kidney-pancreas transplantation, transplanted between 2003 and 2011. Eligible patients had to have protocol kidney biopsy at the time of implantation and 12 months after transplantation. Exclusion criteria have been: dual kidney transplantation, kidney-liver transplantation, use of antithymocyte immunoglobulin, BK nephropathy and recurrence of glomerulonephritis after transplantation.

Immunosuppression:

1
2
3 Induction immunosuppression consisted of an anti-IL2 antibody (daclizumab or
4 basiliximab), calcineurin inhibitor (tacrolimus or cyclosporine), MMF and
5
6 methylprednisolone. Maintenance immunosuppression consisted of a calcineurin
7
8 inhibitor (tacrolimus or cyclosporine), MMF \pm steroids. Target cyclosporine trough
9
10 concentrations were 250-350 during first month posttransplant, 200-300 during second to
11
12 6th month and 100-150 μ g/L thereafter. Target tacrolimus trough levels were 10-12
13
14 during first month, 8-10 during second to 6th month and 5-8 μ g/L thereafter.
15
16
17

18
19 Mycophenolic acid target trough concentration was aimed to be higher than 7.2 μ mol/L
20
21 with tacrolimus and higher than 5 μ mol/L with cyclosporine use.
22
23

24 Daclizumab was administered at day 0: 2mg/kg i.v. before opening of vascular
25
26 anastomosis and at day 14: 2mg/kg i.v.. Basiliximab was administered at day 0: 20 mg
27
28 i.v. before opening of vascular anastomosis and at day 4: 20 mg i.v..
29
30

31 Steroids have been dosed as follows: day 0: intraoperatively 500 mg of
32
33 methylprednisolone, day 1: 250 mg, day 2: 125mg, day 3: 80 mg and day 4: 40 mg. In
34
35 patients with early steroid withdrawal steroids have been withdrawn at day 5 after
36
37 transplantation. In patients maintained on steroids, nadir dose of prednisone was 5 mg/d,
38
39 achieved by 6 months. The criteria for early elimination of steroids were low
40
41 immunological risk of the recipient (absence of, or low degree of HLA sensitization,
42
43 i.e. PRA <10%) and good immediate renal function, as well as absence of an episode of
44
45 acute rejection within 5 days after the transplantation. Steroids have been reintroduced in
46
47 patients who suffered acute rejection episode.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 As prophylaxis for viral (HSV, CMV), fungal (Candida spp.) urinary and P. jiroveci
4
5 infections, low-dose fluconazole (for one year), valganciclovir (universally for three
6
7 months) and sulfomethoxazol and trimethoprim (for one year) was used.
8
9

10
11
12
13
14
15
16
17
18
19
20 *Renal allograft biopsies:*

21
22 Protocol kidney biopsies were done at implantation, 1, 3, 6 and 12 months after
23
24 transplantation. For cause biopsies were done in case of unexplained deterioration of
25
26 renal function, or once weekly in patients with DGF. All rejection episodes were
27
28 histologically confirmed. Histopathological analysis was performed by either of two
29
30 pathologists who were blinded for immunosuppression. Acute rejections and chronic
31
32 allograft scores have been analyzed using Banff 97 classification and its updates.[14, 15]
33

34
35 All protocol and indication biopsies were analyzed by light microscopy, by
36
37 immunofluorescence for C4d, and if indicated by immunohistochemistry for BK virus.
38
39 Biopsies at 1 year post transplant have been also analyzed by electron microscopy for
40
41 signs of chronic antibody-mediated rejection (transplant glomerulopathy, peritubular
42
43 capillary basement membrane multilayering).[16]
44
45
46
47
48

49
50 *Clinical outcome parameters:*

51
52 Progression of chronic allograft scores during 1 year posttransplant was calculated by
53
54 subtracting implantation chronic scores from chronic allograft scores 12 months
55
56
57
58
59
60

1
2
3 posttransplant: interstitial fibrosis (Δci), tubular atrophy (Δct), glomerulosclerosis (Δcg),
4
5 mesangial matrix increase (Δmm), vasculopathy (Δcv) and arteriolar hyalinosis (Δah).
6
7

8 Estimated creatinine clearance (eCrCl) at 3, 6 and 12 months posttransplant was calculated
9
10 using Cockcroft-Gault formula. Acute rejections with Banff grade IA and IB were treated
11
12 with three 500 mg methylprednisolone pulses. In case of acute rejection grade IIA or
13
14 greater, patients have been treated with antithymocyte globulin. Antibody-mediated
15
16 rejections were treated with steroid pulse and plasmapheresis.
17
18

19
20 Average dose of MMF during 1 year posttransplant was calculated from MMF dose at
21
22 month 1, 3, 6 and 12.
23

24 Adverse effects analysed were clinically significant leucopenia, defined as white blood
25
26 cell count less than 3000/ml, time to first symptomatic infection and number of
27
28 symptomatic infection episodes per patient during first post transplant year.
29
30
31
32
33

34 *Statistical analysis:*

35
36 Numerical data are presented as mean \pm SD or median with range in case of not normal
37
38 distribution. Normality of distribution has been tested with Kolmogorov-Smirnov test.
39
40 Correlation between two continuous variables has been tested using Spearman
41
42 nonparametric correlation. Difference between two groups in continuous variables has
43
44 been tested with student t-test or with Mann-Whitney test in non-normally distributed
45
46 variables. The significance of the progression in chronic scores was analyzed using
47
48 Wilcoxon Matched Pairs test. Univariate and multiple linear regression analysis were
49
50 performed to determine predictive factors for progression of chronic allograft scores and
51
52 kidney function at 12 months after transplantation. All variables that were associated with
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

respective outcome in bivariate analysis (at $p \leq 0.1$) were included in multivariate analysis. Because of colinearity between ci and ct score, only one score was included in each multivariate analysis. Statistical significance was considered at $p < 0.05$. All statistical analyses were performed using Statistica 10 (StatSoft, Tulsa, OK, USA).

RESULTS:

Patient and transplant characteristics:

Patient characteristics are shown in Table 1. Recipients were a mean of 44.67 ± 12.03 years old at the time of transplantation, 68 percent of them were male and all were Caucasians. 33 percent of recipients had DGF after transplantation. Donors were a mean of 43.89 ± 15.55 years old and 54 percent of them were male. Number of living donor transplantations was 24 (30 percent). Average daily MMF dose during 1 year posttransplant was 2244 ± 585 mg (1062 – 4000) (Table 2). As expected, there was no correlation of MMF dose with MMF trough concentration ($R = -0.13$; $p = 0.28$). Also, there was no correlation between MMF dose with tacrolimus concentration ($R = -0.04$; $p = 0.79$). Early steroid withdrawal was done in 46 percent of patients after transplantation. Incidence of subclinical and clinical acute rejections greater than borderline was 30 percent in first year. There was no correlation between average MMF dose and incidence of acute rejection ($p = 0.68$).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Factors associating with eCr_{cl}:

Kidney function increased during 1st year post transplant. eCr_{cl} at month 3 was 56.98 ± 15.78 ml/min, at 6 month 58.94 ± 16.94 ml/min and at 12 month 61.47 ± 16.75 ml/min ($p < 0.001$; 12 months vs. 3 months) (Figure 1.) eCr_{cl} at 1 year post transplant was greater in SPKT recipients (71.38 ± 13.45 ml/min vs. 57.88 ± 16.47 ml/min; $p = 0.001$) and in patients who did not have DGF (64.08 ± 15.87 ml/min vs. 56.15 ± 17.55 ml/min; $p = 0.05$). Donor age ($R = -0.46$; $p < 0.001$) and recipient age ($R = -0.46$; $p < 0.001$) negatively correlated with eCr_{cl} at 1 year post transplant, while there was no correlation of renal function with donor and recipient gender, type of donation (deceased vs. living), HLA MM, average CNI concentration, steroid-free regimen of immunosuppression, or history of acute rejection (Table 3). In univariate analysis allograft function at 12 month post Tx was also negatively correlated with ci ($R = -0.34$; $p = 0.002$) and ct ($R = -0.35$; $p = 0.002$) at 12 month (Figure 2A, Figure 2B). Although MMF dose was positively correlated with renal function with borderline significance in univariate analysis, in multivariate analysis there was a significant positive association between greater average MMF dose and better eCr_{cl} at 12 month post transplant ($b = 0.21 \pm 0.1$; $p = 0.04$) (Table 4).

Factors affecting IF/TA:

The average ci score increased from 0.16 ± 0.44 to 0.94 ± 0.86 between implantation and month 12 ($p < 0.001$). Average progression of this and other chronic scores during 1 year post transplant is shown in Table 5. In univariate analysis Δci ($R = -0.37$; $p = 0.001$) and Δct ($R = -0.38$; $p = 0.001$) significantly negatively correlated with average MMF dose (Figure 3A and 3B, Table 6). There was lower progression of ci score in patients on steroid-free

1
2
3 immunosuppression (0.47 ± 0.7 vs. 1.09 ± 0.87 ; $p=0.002$) and in those who did not have
4 DGF (0.62 ± 0.74 vs 1.19 ± 0.98 ; $p=0.02$). Acute cellular rejection, recipient and donor
5 gender, recipient and donor age, HLA MM, deceased vs. living donor, as well as average
6 concentration of tacrolimus had no significant effect on progression of chronic allograft
7 scores. Higher average MMF dose was associated with lower progression of ci and ct
8 score regardless CNI type (data not shown). Factors that remained significantly
9 associated with progression of ci score in multivariate analysis were ci0 score, donor age,
10 average MMF dose, DGF and steroid-free immunosuppression (Table 7.). In multivariate
11 analysis only ct0 score, average MMF dose and DGF remained independently associated
12 with 12-month progression of ct score (Table 7.). Selected AE are shown in Table 8.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

There was no difference in AE (leucopenia and infections) with respect to average median MMF dose.

Discussion:

The most important novel finding in our study is that greater average MMF exposure was strongly negatively correlated with IF/TA progression during first year after kidney transplantation. Patients on higher average dose of MMF during 1 year post transplantation had significantly lower progression of ci and ct scores. To our knowledge this is first study demonstrating that there is a dose-dependent protective effect of MMF on graft IF/TA. Lower progression of IF/TA could not be explained with lower concentration of CNI, because there was not correlation between tacrolimus concentration with IF/TA. Similarly, there was no correlation between average MMF

1
2
3 dose and tacrolimus ($R=-0.04$; $p=0.79$) or cyclosporine concentration ($R=-0.07$, $p=0.79$).

4
5 In addition, higher average MMF dose was not associated with decreased incidence of
6
7
8 biopsy proven acute rejection, which suggests that antifibrotic properties of higher MMF
9
10 dose was at least partly independent of its immunosuppressive effects. Higher MMF dose
11
12 had only moderate effect on 1-year renal function, which is consistent with previous
13
14 reports showing that transplanted kidneys undergo pathohistology changes without
15
16 significant early change in kidney function.[17]

17
18 In the present retrospective study we have confirmed that IF/TA progression occurs in
19
20 first year after kidney transplantation. Several studies have shown that progression of
21
22 IF/TA is correlated with type of immunosuppression.[18] In most transplant centers in
23
24 the United States and Europe immunosuppression consists of induction with an anti-IL2R
25
26 antibody or antithymocyte immunoglobulin and maintenance with a calcineurin inhibitor,
27
28 MMF and steroids.[19] Studies have reported significant improvement in kidney function
29
30 in patients on MMF with lower exposition to CNIs, esp. tacrolimus.[20] Recently, in the
31
32 paper of Kamar *et al.* it has been reported that maintenance kidney transplant patients
33
34 converted to a higher dose of the mycophenolate sodium (1440 mg daily) with lower
35
36 tacrolimus concentration had borderline higher eCr_{cl} on month 6 *vs.* those treated with
37
38 lower dose of mycophenolate sodium, with usual tacrolimus concentration (eCr_{cl} $49.1 \pm$
39
40 11.1 *vs.* 44.7 ± 11.5 ml/min; $p=0.07$).[21] Although there was only borderline
41
42 significance, increased mycophenolate dosing with lower tacrolimus concentration was
43
44 safe with potential benefit on kidney function.
45
46
47
48
49
50
51

52
53 Our study also corroborates recently published findings of a *post hoc* joint analysis of the
54
55 Symphony, FDCC and OptiCept trials, where a lower tacrolimus level and a higher
56
57
58
59
60

1
2
3 MMF dose were associated with significantly better kidney function at 1 year post
4 transplant.[22] Shortcoming of these studies[17,18] is lack of protocol biopsies. The
5
6 optimal MMF dosing in patients maintained on contemporary low-dose CNI is still
7
8 undetermined. However, some results of early MMF registration trials suggest that higher
9
10 MMF exposure might be beneficial; having in mind that there was no antibody induction
11
12 in these studies and that CNI was standard dose cyclosporine. Thus, in the Tri-continental
13
14 study, group treated with 3 g MMF compared with 2 g of MMF showed lower incidence
15
16 of biopsy proven acute rejection episodes (15.9% vs. 19.7%) within 6 month period
17
18 selected for the primary efficacy analysis. Similarly, serum creatinine level at 1 year was
19
20 1.42 ± 0.07 mg/dL in the MMF 3 g group vs. 1.64 ± 0.07 mg/dL in MMF 2 g group.[12]
21
22 In the European mycophenolate mofetil study same trends regarding higher MMF dose
23
24 were observed.[11] As mentioned before, in these studies there was no antibody
25
26 induction that could have allowed lower dose of cyclosporin with higher dose of MMF
27
28 and there were no protocol biopsies. In a more recent MYSS trial, there was no difference
29
30 in acute rejection rate and renal function between MMF and azathioprine in a
31
32 cyclosporine-based protocol.[19] However in that study only one MMF dose was
33
34 compared to azathioprine[23] and again there were no protocol biopsies.
35
36
37 Unfortunately adequate prospective MMF dose comparison studies in tacrolimus-based
38
39 protocols with antibody induction are missing. In the Symphony study it was reported
40
41 that patients on tacrolimus-MMF-prednisone maintenance immunosuppression after kidney
42
43 transplantation had better kidney function and graft survival with lower number of acute
44
45 rejection episodes. Patients in that group had highest MMF exposure.[24] Protocols with
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 even higher MMF exposure might allow additional CNI sparing, that would decrease side
4 effect of CNI (hypertension, diabetes, hyperlipidemia, neurotoxicity).[25]
5

6
7
8 Clinical relevance of IF/TA without other concomitant pathology (i.e. recurrent disease
9 and chronic antibody-mediated rejection) for prediction of graft deterioration and loss is
10 controversial. In El-Zoghby et al. study there was attempt to identify specific causes of
11 late kidney allograft failure. The authors found that transplant glomerulopathy was
12 responsible for 37 percent loss of functioning grafts, while graft loss due to IF/TA was
13 present in 31 percent of cases (with higher frequency in deceased-donor transplants).[26]
14

15
16
17 At first glance, these results seem at odd with ours, where there were no signs of chronic
18 antibody-mediated rejection. An explanation for this discrepancy in the results of the two
19 studies is not completely clear, but the former study included high number of living
20 transplants (72.5 percent) with glomerulonephritis as primary disease and with follow-up
21 up to 10 years. Transplant glomerulopathy is more frequently seen late posttransplant,
22 generally with low incidence. Nevertheless, ours and El-Zoghby study, both
23 demonstrated that IF/TA even in absence of other pathology is associated with adverse
24 graft outcome. Another important study, the DeKaf study, tried to use various
25 histopathologic clusters to differentiate subgroups within diagnosis of IF/TA. They found
26 that cluster with more severe fibrosis plus inflammation and arterial lesions had the worst
27 prognosis.[27] Although incidence of acute rejection in our study did not vary with MMF
28 exposure, increased MMF exposure might suppress mild graft inflammation, below the
29 threshold for diagnosing acute rejection. This is subject of our ongoing investigation and
30 will be reported separately. An interesting finding of the present study was that early
31 steroid withdrawal was not associated with worse IF/TA. At first glance this is at odd
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 with the Astellas trial.[23] However, according to our protocol, patients with DGF were
4
5 not included in early steroid withdrawal and Astellas trial, which did not have protocol
6
7 biopsies, reported increased IF/TA in early steroid withdrawal group based on indication
8
9 biopsies performed early posttransplant, thus more likely reflecting donor-derived
10
11 histology changes, rather than effect of steroid withdrawal.[28]
12

13
14
15 In our study there was only borderline significance of positive association of 1-year eCr_{cl}
16
17 with MMF in univariate analysis. This result is not very surprising since decreased renal
18
19 function is not a very sensitive marker of incipient IF/TA.
20

21
22 Mechanisms by which an average higher exposure to MMF was associated with slower
23
24 progression of IF/TA may be both immune and nonimmune. Because there was no
25
26 difference in incidence of acute rejection with respect to increased MMF exposure in our
27
28 study, we believe that there may be a significant contribution of nonimmune mechanisms
29
30 in retardation of IF/TA in patients with higher MMF. In line with this, in many
31
32 experimental models it has been shown that MMF has antiproliferative and antifibrotic
33
34 effect.[29-31] In the study of Jiang at al. using rat renal ischemia reperfusion injury, a
35
36 time- and dose-dependent correlation of higher MMF dose with better renal function and
37
38 lower interstitial fibrosis was demonstrated. Suggested potential mechanism was lower
39
40 expression of TGF- β 1 and MCP-1 with lower macrophage infiltration.[32] In recent
41
42 clinical trials MMF was shown as a safe drug that could be a good candidate for
43
44 treatment of interstitial lung disease in systemic sclerosis.[33] Experimental model of
45
46 encapsulated peritoneal sclerosis in rats proved beneficial effect of MMF as an inhibitor
47
48 of neovascularisation.[34] Also, MMF monotherapy was associated with a positive effect
49
50 on hepatic fibrosis progression in HCV liver transplant recipients.[35]
51
52
53
54
55
56
57
58
59
60

1
2
3 Our study has several shortcomings, such as its retrospective aspect and relatively short
4 study period. Although study period was limited to 12 months post transplantation, a
5 clear correlation of slower progression of IF/TA with higher average MMF dose
6 underlines potential benefit of these findings. As mentioned before, in current study we
7 did not analyze inflammation outside Banff acute rejection threshold in kidney biopsies
8 with respect to MMF dose. As inflammation in areas of IF/TA is an important predictor
9 of renal function and graft loss, this is subject of an ongoing work.

10 In summary, higher MMF dose after kidney transplantation might slower progression of
11 IF/TA, which might lead to better long-term survival of transplanted kidney. Our study
12 serves as a platform for a prospective, randomized, long-term trial with different MMF
13 doses to evaluate benefit of higher MMF dose in renal transplant recipients.

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30 (NCT018600183).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgments:

This manuscript has not been published elsewhere, beside as a part of 2011 ASN Annual meeting abstract.

Contributorship Statement

Karlo Mihovilović – participated in research design, collecting data, analyzing data and wrote the paper, karlomihovilovic@gmail.com

Bojana Maksimović - participated in collecting and analyzing data, bmaximovic@gmail.com

Branislav Kocman - participated in collecting data, branislav.kocman@gmail.com

Denis Guštin - participated in collecting data, denis.gustin@zg.t-com.hr

Željko Vidas – participated in collecting data, zeljko.vidas1@zg.t-com.hr

Stela Bulimbašić - participated in collecting and analyzing data, stela.bulimbasic@gmail.com

Danica Galešić Ljubanović – participated in collecting and analyzing data,

danica.ljubanovic@zg.htnet.hr

Mirjana Sabljar Matovinović – participated in collecting data, mirjana.sabljar-

matovinovic@zg.t-com.hr

Mladen Knotek- proposed research design, analyzed data and participated in writing the paper,

mladen.knotek1@zg.t-com.hr

Support and Financial Disclosure Declaration:

Source of support: Grant by the Ministry of Science, Technology and Sports of the Republic of Croatia to Dr. Mladen Knotek.

Disclosures:

The authors of this manuscript have no conflicts of interest to disclose.

Data Sharing Statement: No additional data available.

Abbreviations:

IF/TA - interstitial fibrosis and tubular atrophy

MMF - mycophenolate mofetil

BK - polyoma virus BK

CNI - calcineurin inhibitors

DGF - delayed graft function

eCrCl - estimated creatinine clearance

SPKT - simultaneous pancreas kidney transplantation

HLA MM – human leukocyte antigen mismatch

AE - adverse events

Figure Legends

Figure 1: Estimated creatinine clearance during first year posttransplant

Figure 2A: Correlation between average MMF dose and progression of ci score

Figure 2B: Correlation between average MMF dose and progression of ct score

Figure 3A: Estimated creatinine clearance by ci score

Figure 3B: Estimated creatinine clearance by ct score

Reference List

- 1 Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. *N Engl J Med* 2002; 346:580-590.
- 2 Kuypers DR, Chapman JR, O'Connell PJ et al. Predictors of renal transplant histology at three months. *Transplantation* 1999; 67:1222-1230.
- 3 Matas AJ, Gillingham KJ, Payne WD et al. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). *Transplantation* 1994;57:857-859.
- 4 Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. *N Engl J Med* 2003; 349:2326-2333.
- 5 Birnbaum LM, Lipman M, Paraskevas S et al. Management of chronic allograft nephropathy: a systematic review. *Clin J Am Soc Nephrol* 2009; 4:860-865.
- 6 Frimat L, Cassuto-Viguiet E, Charpentier B et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. *Am J Transplant* 2006; 6:2725-2734.
- 7 Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. *N Engl J Med* 2007; 357:2562-2575.
- 8 Azuma H, Binder J, Heemann U et al. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. *Transplantation* 1995; 59:460-466.
- 9 Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. *Transplantation* 2000; 69:2405-2409.
- 10 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. *Transplantation* 1996; 61,722-729.
- 11 European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. *Lancet* 1995; 345, 1321-1325.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 12 Djamali A, Vidyasagar A, Yagci G et al. Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway. *Transplantation* 2010;90:387-393.
 - 13 Dell'Oglio MP, Zaza G, Rossini M et al. The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. *J Am Soc Nephrol* 2010; 21:2157-2168.
 - 14 Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. *Am J Transplant* 2008; 8:753-760.
 - 15 Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. *Kidney Int* 1999; 55:713-723.
 - 16 Roufosse CA, Shore I, Moss J et al. Peritubular capillary basement membrane multilayering on electron microscopy: a useful marker of early chronic antibody-mediated damage. *Transplantation* 2012; 94:269-274.
 - 17 Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. *N Engl J Med* 2003; 349:2326-2333.
 - 18 Gelens MA, Steegh FM, van Hooff JP et al. Immunosuppressive Regimen and Interstitial Fibrosis and Tubules Atrophy at 12 Months Postrenal Transplant. *Clin J Am Soc Nephrol* 2012; 5:1010-1017.
 - 19 Available at:
http://srrtr.transplant.hrsa.gov/annual_reports/2011/pdf/01_kidney_12.pdf. 2013.
 - 20 Ekberg H, van GT, Kaplan B et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. *Transplantation* 2011; 92:82-87.
 - 21 Kamar N, Rostaing L, Cassuto E et al. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. *Clin Nephrol* 2012 ;77:126-136.
 - 22 Ekberg H, van GT, Kaplan B et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. *Transplantation* 2011; 92:82-87.
 - 23 Remuzzi G, Lesti M, Gotti E et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. *Lancet* 2004; 364:503-512.
 - 24 Lloberas N, Torras J, Cruzado JM et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic

- 1
2
3 Substudy within the Symphony Study. *Nephrol Dial Transplant* 2011; 26:3784-
4 3793.
5
6
7 25 Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes
8 after renal transplantation. *N Engl J Med* 2002; 346:580-590.
9
10 26 El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney
11 allograft loss. *Am J Transplant* 2009;9:527-535.
12
13 27 Matas AJ, Leduc R, Rush D et al. Histopathologic clusters differentiate subgroups
14 within the nonspecific diagnoses of CAN or CR: preliminary data from the
15 DeKAF study. *Am J Transplant* 2010; 10:315-323.
16
17
18 28 Woodle ES, First MR, Pirsch J et al. A prospective, randomized, double-blind,
19 placebo-controlled multicenter trial comparing early (7 day) corticosteroid
20 cessation versus long-term, low-dose corticosteroid therapy. *Ann Surg*; 248: 564-
21 577.
22
23
24 29 Luo L, Sun Z, Wu W et al. Mycophenolate mofetil and FK506 have different
25 effects on kidney allograft fibrosis in rats that underwent chronic allograft
26 nephropathy. *BMC Nephrol* 2012;13:53.
27
28
29 30 Jiang S, Tang Q, Rong R et al. Mycophenolate mofetil inhibits macrophage
30 infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. *Eur J*
31 *Pharmacol* 2012; 688:56-61.
32
33 31 Dell'Oglio MP, Zaza G, Rossini M et al. The anti-fibrotic effect of mycophenolic
34 acid-induced neutral endopeptidase. *J Am Soc Nephrol* 2010; 21:2157-2168.
35
36
37 32 Jiang S, Tang Q, Rong R et al. Mycophenolate mofetil inhibits macrophage
38 infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. *Eur J*
39 *Pharmacol* 2012; 688:56-61.
40
41 33 Tzouveleakis A, Galanopoulos N, Bouros E, et al. Effect and safety of
42 mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung
43 disease: a meta-analysis. *Pulm Med* 2012; 1-7.
44
45
46 34 Hur E, Bozkurt D, Timur O, et al. The effects of mycophenolate mofetil on
47 encapsulated peritoneal sclerosis model in rats. *Clin Nephrol* 2012; 77:1-7.
48
49 35 Manzia TM, Angelico R, Toti L et al. Long-term, maintenance MMF
50 monotherapy improves the fibrosis progression in liver transplant recipients with
51 recurrent hepatitis C. *Transpl Int* 2011; 24:461-468.
52
53
54
55
56
57
58
59
60

Table 1. Baseline characteristics

RECIPIENT CHARACTERISTICS	AGE (years)	44.67 ± 12.03
	GENDER (f/m)	25/54
	PRIMARY RENAL DISEASE (diabetes mellitus, polycystic kidney disease, glomerulonephritis, pyelonephritis/interstitial nephritis, other/unknown)	24/8/19/6/22
DONOR CHARACTERISTICS	DONOR SOURCE (deceased/living)	55/24
	AGE (years)	43.89 ± 15.55
	GENDER (f/m)	36/43
TRANSPLANTATION CHARACTERISTICS	TRANSPLANTED ORGAN (KIDNEY/SPKT)	58/21
	INITIAL IMMUNOSUPPRESSION (anti-IL2,TAC,MMF/anti-IL2, CyA,MMF)	53/26
	DELAYED GRAFT FUNCTION (no/yes)	53/26
	STEROID FREE (yes/no)	36/43
	HLA MM	3.33 ± 1.51

Table 2. eCr_{cl}, MMF dose and CNI concentration during first year post transplant

	Month posttransplant			
	1	3	6	12
eCr _{cl} (ml/min)		56.98 ± 15.79	58.94 ± 16.94	61.47 ± 16.75
MMF dose (mg)	2500 (750 – 4000) 2427 ± 643.17	2000 (750 – 4000) 2167.72 ± 733.49	2000 (1000-4000) 2188.29 ± 716.91	2000 (1000-4000) 2193.04 ± 642.95
Tacrolimus conc. (µg/L) (n=53)	10.79 ± 4.16	9.69 ± 3.00	9.03 ± 5.52	7.83 ± 2.45
Cyclosporin conc. (µg/L) (n=26)	335.07 (274 – 413)	231.05 (181-265)	206 (170 – 257)	131 (125 – 171)

Table 3. Association of variables with eCr_{cl} on 1 year

	Estimated creatinine clearance (ml/min)	p value
Kidney vs. SPKT	57.88 ± 15.47 vs. 71.38 ± 13.45	0.001
DGF (yes vs. no)	56.15 ± 17.55 vs. 64.08 ± 15.87	0.05
Recipient gender (m vs. f)	59.83 ± 16.02 vs. 65 ± 18.07	0.2
Donor gender (m vs. f)	63.87 ± 16.71 vs. 58.60 ± 16.58	0.17
Donor source (D vs. L)	62.36 ± 17.85 vs. 59.43 ± 14.05	0.47
Steroid-free (yes vs. no)	63.94 ± 17.73 vs. 59.39 ± 15.81	0.23
Acute rejection (yes vs. no)	61.64 ± 16.59 vs. 61.39 ± 16.97	0.95
	R	p value
Recipient age	-0.45	<0.001
Donor age	-0.46	<0.001
HLA MM	0.07	0.52
Average tacrolimus concentration	-0.02	0.9
Average MMF dose	0.18	0.1
ci at 1 year post Tx	-0.34	0.002
ct at 1 year post Tx	-0.35	0.002
cv at 1 year post Tx	-0.20	0.07

Table 4. Multiple regression analysis of factors associated with kidney function

	Beta (β)	St.Err. β	p value
Tx (kidney)	-0.17	0.13	0.19
DGF (no)	0.04	0.1	0.71
Recipient age	-0.41	0.1	<0.001
Donor age	-0.1	0.14	0.45
ci at 12 months	-0.18	0.11	0.09
Average MMF dose	0.21	0.1	0.04

Table 5. One-year progression of chronic allograft scores

Banff score	N	At transplantation	N	12 month	p
Interstitial fibrosis (ci)	79	0.16 ± 0.44	79	0.94 ± 0.85	<0.001
Tubular atrophy (ct)	79	0.24 ± 0.46	79	1.05 ± 0.77	<0.001
Chronic glomerulopathy (cg)	79	0	79	0	
Mesangial matrix (mm)	79	0.01 ± 0.11	79	0.09 ± 0.36	0.09
Fibrointimal thickening (cv)	76	0.37 ± 0.83	78	0.29 ± 0.70	0.47
Arteriolar hyalinosis (ah)	78	0.68 ± 1.04	79	0.79 ± 1.04	0.26

Table 6. Correlation of factors associated with progression of ci and ct scores

	Δ ci		Δ ct	
	mean \pm SD	p	mean \pm SD	p
Kidney vs. SPKT	0.86 \pm 0.91 vs. 0.67 \pm 0.73	0.51	0.85 \pm 0.87 vs. 0.86 \pm 0.65	0.74
DGF (yes vs. no)	1.19 \pm 0.98 vs. 0.62 \pm 0.74	0.02	1.15 \pm 0.92 vs. 0.69 \pm 0.72	0.05
Recipient gender (m vs. f)	0.83 \pm 0.88 vs. 0.76 \pm 0.83	0.78	0.91 \pm 0.83 vs. 0.72 \pm 0.79	0.35
Donor gender (m vs. f)	0.91 \pm 0.95 vs. 0.69 \pm 0.75	0.43	0.88 \pm 0.93 vs. 0.81 \pm 0.67	0.96
Donor source (D vs. L)	0.84 \pm 0.88 vs. 0.75 \pm 0.85	0.73	0.87 \pm 0.82 vs. 0.79 \pm 0.83	0.71
Steroid free (no vs. yes)	1.09 \pm 0.87 vs. 0.47 \pm 0.74	0.002	1.07 \pm 0.83 vs. 0.58 \pm 0.73	0.01
Acute rejection (yes vs. no)	0.8 \pm 0.89 vs. 0.83 \pm 0.82	0.78	0.93 \pm 0.84 vs. 0.67 \pm 0.76	0.23
	R	p	R	p
Recipient age	-0.11	0.33	-0.11	0.32
Donor age	0.17	0.13	0.04	0.73
HLA MM	-0.09	0.43	-0.002	0.99
Average tacrolimus conc.	-0.009	0.95	0.003	0.98
Average MMF dose	-0.37	<0.001	-0.38	<0.001
ci at implantation	-0.32	0.003		
ct at implantation			-0.45	<0.001

Table 7. Multivariate general regression analysis for factors related to progression of ci and ct score


Δci			
	Beta (β)	Std. Err. β	p
ci0	-0.43	0.09	<0.001
DGF (no)	-0.22	0.11	<0.05
Average MMF dose	-0.20	0.09	<0.05
Donor age	0.32	0.09	<0.05
Steroid free (yes)	-0.25	0.11	0.02
Δct			
	Beta (β)	Std. Err. β	p
ct0	-0.44	0.09	<0.001
Average MMF dose	-0.29	0.1	<0.05
DGF (no)	-0.29	0.1	<0.05
Steroid free (yes)	-0.09	0.11	0.39

Table 8. Adverse events with respect to 1 year average median MMF dose.

	MMF dose < median	MMF dose > median	p
Average number of infection episodes per patient	1.16 ± 0.97	1.23 ± 1.22	0.88
Mean time to first infection (days)	157±138	175±143	0.76
Proportion of patients with leucopenia	6 /31	7 /48	0.58

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 1: Estimated creatinine clearance during first year posttransplant



*; p<0.001; 3 month vs. 12 months eCrCl. Values are shown as mean ±SD

90x105mm (300 x 300 DPI)


Figure 2A: Correlation between average MMF dose and progression of ci score



90x121mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 2B: Correlation between average MMF dose and progression of ct score



90x121mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3A: Estimated creatinine clearance by ci score



* $p < 0.05$; score ci 0 vs. score ci 3 (*post hoc* Newman-Keuls test)


** $p = 0.03$; score ci 1 vs. score ci 3

Values are shown as mean \pm SD

90x121mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 3B: Estimated creatinine clearance by ct score



* $p < 0.05$; score ct 0 vs. score ct 3 (post hoc Newman-Keuls test)

** $p = 0.03$; score ct 1 vs. score ct 3

Values are shown as mean \pm SD

90x121mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No/page number	Recommendation
Title and abstract	1/1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2/5	Explain the scientific background and rationale for the investigation being reported
Objectives	3/5,6	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4/6	Present key elements of study design early in the paper
Setting	5/6,7,8,9	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6/6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7/6,7,8	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/measurement	8*/8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10/6	Explain how the study size was arrived at
Quantitative variables	11/9	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12/9	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

Results

Participants	13* /9, 10	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14* /9, 10	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15* /11	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16/ 10, 11	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18/ 12	Summarise key results with reference to study objectives
Limitations	19/ 16	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20/ 12- 16	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21/ 12- 16	Discuss the generalisability (external validity) of the study results

Other information

Funding	22/ 2	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----------	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.